<!DOCTYPE html>
<html xmlns="https://www.w3.org/1999/xhtml" class="fa-events-icons-ready gr__clinicaltrials_gov" lang="en">


<div id="main-content">

<div class="indent2">
        	<h1 class="solo_record">Efficacy and Safety Study of Elagolix Versus Placebo or Leuprorelin Acetate in Endometriosis</h1>

  <div class="row">
    <div class="column left">
      <div class="usa-alert usa-alert-warning" style="clear:both;margin:2ex 2em;">
        <table>
          <tbody><tr>
            <td style="width:5%">
              <img src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20Versus%20Placebo%20or%20Leuprorelin%20Acetate%20in%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/warning.png" style="width:1.3em;" alt="">
            </td>
            <td>
              The safety and scientific validity of this study is the 
responsibility of the study sponsor and investigators. Listing a study 
does not mean it has been evaluated by the U.S. Federal Government.
                            Read our <a href="https://clinicaltrials.gov/ct2/about-site/disclaimer">disclaimer</a> for details.
            </td>
          </tr>
        </tbody></table>
      </div>      </div> 
<!--
  <div style="float:right;margin-right:4em">ClinicalTrials.gov Identifier: NCT00797225</div>
-->
    <div class="column right">
  <table style="width:90%">
  <tbody><tr><td>ClinicalTrials.gov Identifier: NCT00797225</td>
  </tr>
  <tr><td>
      
       
              <div class="not-recruiting-status">
                        <span style="display:inline;" class="term" data-term="recruitment status" title="Show definition" tabindex="0">Recruitment Status <i class="fa fa-info-circle term" aria-hidden="true" data-term="recruitment status" style="border-bottom-style:none;" title="Show definition" tabindex="0"></i></span>: 
                    Completed
                  
                
  <div style="font-size:inherit">
  <span style="display:inline;" class="term" data-term="first posted" title="Show definition" tabindex="0">First Posted <i class="fa fa-info-circle term" aria-hidden="true" data-term="first posted" style="border-bottom-style:none;" title="Show definition" tabindex="0"></i></span>: November 25, 2008</div>
      <div style="font-size:inherit">
    <span style="display:inline;" class="term" data-term="results first posted" title="Show definition" tabindex="0">Results First Posted <i class="fa fa-info-circle term" aria-hidden="true" data-term="results first posted" style="border-bottom-style:none;" title="Show definition" tabindex="0"></i></span>: September 10, 2018</div>
    <div style="font-size:inherit">
  <span style="display:inline;" class="term" data-term="last update posted" title="Show definition" tabindex="0">Last Update Posted <i class="fa fa-info-circle term" aria-hidden="true" data-term="last update posted" style="border-bottom-style:none;" title="Show definition" tabindex="0"></i></span>: September 10, 2018</div>

  
      </div>
  </td>
  </tr>
  </tbody></table>
  </div>
  </div>


                <div class="info-title">Sponsor:</div>
                <div class="info-text" id="sponsor"> AbbVie </div>

                              <div class="info-title">Information provided by (Responsible Party):</div>
                <div class="info-text" id="responsibleparty">AbbVie</div>
              	</div>
<br>


<div id="tabs">
    <ul id="tab-links">
		<li id="full-text"><a href="https://clinicaltrials.gov/ct2/show/study/NCT00797225?sect=X01256">Study Details</a></li>
		<li id="tabular"><a href="https://clinicaltrials.gov/ct2/show/record/NCT00797225?sect=X01256">Tabular View</a></li>
  					<li id="results" class="current"> Study Results</li>
				<li id="disclaimer"><a title="Disclaimer - opens new window" href="https://clinicaltrials.gov/ct2/about-site/disclaimer" onclick="openNewWindow('/ct2/about-site/disclaimer'); return false">Disclaimer</a></li>
		<li id="howtoread"><a title="How to Read a Study Record - opens new window" href="https://clinicaltrials.gov/ct2/help/how-read-study" onclick="openNewWindow('/ct2/help/how-read-study'); return false">How to Read a Study Record</a></li>
    </ul>
</div>  <!--
<div style="background-color:#f6f6f6;margin-top:5.0ex;padding-bottom:1.5ex;"> </div>
-->

  <div id="tab-body">
  <div class="indent2" style="background-color:white;">
  <!-- Title section -->
  <div class="indent3" style="text-align:center;">
    
  
  <table class="data_table" style="margin:3ex 0;" width="80%" cellspacing="0" cellpadding="5" border="1">

        <tbody><tr>
      <th class="header3 pale_banner_color" style="text-align:right;white-space:nowrap;">Study Type: </th>
      <td class="body3" style="text-align:left;">Interventional</td>
    </tr>
    
        <tr>
      <th class="header3 pale_banner_color" style="text-align:right;white-space:nowrap;">Study Design: </th>
      <td class="body3" style="text-align:left;">Allocation:&nbsp;Randomized;
 &nbsp; Intervention&nbsp;Model:&nbsp;Parallel&nbsp;Assignment; &nbsp; 
Masking:&nbsp;Quadruple&nbsp;(Participant,&nbsp;Care&nbsp;Provider,&nbsp;Investigator,&nbsp;Outcomes&nbsp;Assessor);
 &nbsp; Primary&nbsp;Purpose:&nbsp;Treatment</td>
    </tr>
    
        <tr>
      <th class="header3 pale_banner_color" style="text-align:right;white-space:nowrap;">
         Condition:       </th>
      <td class="body3" style="text-align:left;white-space:nowrap;">
                Endometriosis<br>
              </td>
    </tr>
    
        <tr>
      <th class="header3 pale_banner_color" style="text-align:right;white-space:nowrap;">
        Interventions:       </th>
      <td class="body3" style="text-align:left;white-space:nowrap;">
                Drug: Leuprorelin Acetate Depot<br>
                Drug: Elagolix<br>
                Drug: Placebo to Elagolix<br>
                Drug: Placebo to Leuprorelin Acetate<br>
              </td>
    </tr>
    
  </tbody></table>

  
  </div>
  
<!-- participant flow section -->
<div class="indent1">

  <br>
  <img src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20Versus%20Placebo%20or%20Leuprorelin%20Acetate%20in%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/triangle.gif" alt=""><span class="header2">&nbsp; Participant Flow</span>

  <a name="part" id="part"></a>
  <div class="header3 indent2">

        <div style="margin-top:1.0ex;">      
      <a title="Hide participant flow" href="https://clinicaltrials.gov/ct2/show/results/NCT00797225?sect=X1256#part">
        <img style="float:left" src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20Versus%20Placebo%20or%20Leuprorelin%20Acetate%20in%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/minus.gif" alt="" border="0"> &nbsp; Hide Participant Flow
      </a>
    </div>

    <br>
    <span class="header3">Recruitment Details</span>
    <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
      <tbody><tr>
        <th class="header3 bold_participant_color" style="text-align:left;">
          Key information relevant to the recruitment process for the
          overall study, such as dates of the recruitment period and locations
        </th>
      </tr>
      <tr>
        <td class="body3 pale_participant_color" style="vertical-align:top;">
                      The study was conducted from 26 November 2008 to 
24 February 2010 at 27 centers in Central Eastern Europe (Bulgaria, 
Hungary, Poland, Romania, Russia and Ukraine).
                  </td>
      </tr>
    </tbody></table>

    <br>
    <span class="header3">Pre-Assignment Details</span>
    <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
      <tbody><tr>
        <th class="header3 bold_participant_color" style="text-align:left;">
          Significant events and approaches for the overall study
          following participant enrollment, but prior to group assignment
        </th>
      </tr>
      <tr>
        <td class="body3 pale_participant_color" style="vertical-align:top;">
                      Patients were randomized equally to oral elagolix 
150 mg or 250 mg once daily, placebo or leuprorelin acetate (LA) 1-month
 depot 3.75 mg injection for 12 weeks. Thereafter, patients originally 
randomized to placebo or LA were re-randomized to 1 of the elagolix 
doses and patients randomized to elagolix continued their assigned dose 
for 12 weeks.
                  </td>
      </tr>
    </tbody></table>

    
    <br>
        
      
            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_participant_color">&nbsp;</th>
      <th class="header3 bold_participant_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_participant_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_participant_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and placebo intramuscular injection once a month for 12 weeks. At 
the end of 12 weeks participants were re-randomized to receive one of 
the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_participant_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_participant_color" style="vertical-align:top;">
                          Participants received elagolix 150 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 150 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_participant_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 250 mg</th>
          <td class="body3 pale_participant_color" style="vertical-align:top;">
                          Participants received elagolix 250 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 250 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_participant_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Leuprorelin</th>
          <td class="body3 pale_participant_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and leuprorelin acetate 1-month depot 3.75 mg intramuscular 
injection once a month for 12 weeks. At the end of 12 weeks participants
 were re-randomized to receive one of the two doses of elagolix (150 mg 
or 250 mg) for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_participant_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo / Elagolix 150 mg</th>
          <td class="body3 pale_participant_color" style="vertical-align:top;">
                          Participants initially randomized to placebo 
were re-randomized at week 12 to receive elagolix 150 mg for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_participant_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo / Elagolix 250 mg</th>
          <td class="body3 pale_participant_color" style="vertical-align:top;">
                          Participants initially randomized to placebo 
were re-randomized at week 12 to receive elagolix 250 mg for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_participant_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Leuprorelin / Elagolix 150 mg</th>
          <td class="body3 pale_participant_color" style="vertical-align:top;">
                          Participants initially randomized to 
leuprorelin acetate were re-randomized at week 12 to receive elagolix 
150 mg for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_participant_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Leuprorelin / Elagolix 250 mg</th>
          <td class="body3 pale_participant_color" style="vertical-align:top;">
                          Participants initially randomized to 
leuprorelin acetate were re-randomized at week 12 to receive elagolix 
250 mg for 12 weeks.
                      </td>
        </tr>
      </tbody></table>

      <br>
              <span class="header3">Participant Flow for 2 periods<br><br></span>
      
                    
        <span class="header3">Period 1: &nbsp; Weeks 1 to 12</span>
        <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0">
          <tbody><tr>
                          <th class="brt bold_participant_color" style="max-width:50%">&nbsp;</th>
                                                      <th class="header3 brt bold_participant_color" style="max-width:20%; text-align:center;">
                              &nbsp; 
                Placebo
              </th>
                                          <th class="header3 brt bold_participant_color" style="max-width:20%; text-align:center;">
                              &nbsp; 
                Elagolix 150 mg
              </th>
                                          <th class="header3 brt bold_participant_color" style="max-width:20%; text-align:center;">
                              &nbsp; 
                Elagolix 250 mg
              </th>
                                          <th class="header3 brt bold_participant_color" style="max-width:20%; text-align:center;">
                              &nbsp; 
                Leuprorelin
              </th>
                                          <th class="header3 brt bold_participant_color" style="max-width:20%; text-align:center;">
                              &nbsp; 
                Placebo / Elagolix 150 mg
              </th>
                                          <th class="header3 brt bold_participant_color" style="max-width:20%; text-align:center;">
                              &nbsp; 
                Placebo / Elagolix 250 mg
              </th>
                                          <th class="header3 brt bold_participant_color" style="max-width:20%; text-align:center;">
                              &nbsp; 
                Leuprorelin / Elagolix 150 mg
              </th>
                                          <th class="header3 brt bold_participant_color" style="max-width:20%; text-align:center;">
                              &nbsp; 
                Leuprorelin / Elagolix 250 mg
              </th>
                      </tr>
                
                
                          <tr>
                <th class="header3 brt bold_participant_color" style="text-align:left;">
                  STARTED&nbsp;                                  </th>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;43&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;43&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;44&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;44&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;0&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;0&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;0&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;0&nbsp;                  </td>
                              </tr>
              
                            
                          <tr>
                <th class="header3 brt bold_participant_color" style="text-align:left;">
                  Received Study Drug&nbsp;                                  </th>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;43&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;43&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;44&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;44&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;0&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;0&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;0&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;0&nbsp;                  </td>
                              </tr>
              
                            
                          <tr>
                <th class="header3 brt bold_participant_color" style="text-align:left;">
                  COMPLETED&nbsp;                                  </th>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;41&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;42&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;43&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;44&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;0&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;0&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;0&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;0&nbsp;                  </td>
                              </tr>
              
                            
                          <tr>
                <th class="header3 brt bold_participant_color" style="text-align:left;">
                  NOT COMPLETED&nbsp;                                  </th>
                                                      <td class="header3 brt pale_participant_color" style="text-align:center;">
                      &nbsp;2&nbsp;                    </td>
                                      <td class="header3 brt pale_participant_color" style="text-align:center;">
                      &nbsp;1&nbsp;                    </td>
                                      <td class="header3 brt pale_participant_color" style="text-align:center;">
                      &nbsp;1&nbsp;                    </td>
                                      <td class="header3 brt pale_participant_color" style="text-align:center;">
                      &nbsp;0&nbsp;                    </td>
                                      <td class="header3 brt pale_participant_color" style="text-align:center;">
                      &nbsp;0&nbsp;                    </td>
                                      <td class="header3 brt pale_participant_color" style="text-align:center;">
                      &nbsp;0&nbsp;                    </td>
                                      <td class="header3 brt pale_participant_color" style="text-align:center;">
                      &nbsp;0&nbsp;                    </td>
                                      <td class="header3 brt pale_participant_color" style="text-align:center;">
                      &nbsp;0&nbsp;                    </td>
                                                </tr>
                              <tr>
                  <td class="header3 br bold_participant_color" style="padding-left:2em;">
                    Adverse Event&nbsp;                                      </td>
                                                            <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 1&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                                      </tr>
                              <tr>
                  <td class="header3 br bold_participant_color" style="padding-left:2em;">
                    Non-compliance&nbsp;                                      </td>
                                                            <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 1&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                                      </tr>
                              <tr>
                  <td class="header3 br bold_participant_color" style="padding-left:2em;">
                    Lack of Efficacy&nbsp;                                      </td>
                                                            <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 1&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                                      </tr>
                              <tr>
                  <td class="header3 br bold_participant_color" style="padding-left:2em;">
                    Sponsor Decision&nbsp;                                      </td>
                                                            <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 1&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                                      </tr>
                                            </tbody></table>
      
                <br>
        
                    
        <span class="header3">Period 2: &nbsp; Weeks 13 to 24</span>
        <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0">
          <tbody><tr>
                          <th class="brt bold_participant_color" style="max-width:50%">&nbsp;</th>
                                                      <th class="header3 brt bold_participant_color" style="max-width:20%; text-align:center;">
                              &nbsp; 
                Placebo
              </th>
                                          <th class="header3 brt bold_participant_color" style="max-width:20%; text-align:center;">
                              &nbsp; 
                Elagolix 150 mg
              </th>
                                          <th class="header3 brt bold_participant_color" style="max-width:20%; text-align:center;">
                              &nbsp; 
                Elagolix 250 mg
              </th>
                                          <th class="header3 brt bold_participant_color" style="max-width:20%; text-align:center;">
                              &nbsp; 
                Leuprorelin
              </th>
                                          <th class="header3 brt bold_participant_color" style="max-width:20%; text-align:center;">
                              &nbsp; 
                Placebo / Elagolix 150 mg
              </th>
                                          <th class="header3 brt bold_participant_color" style="max-width:20%; text-align:center;">
                              &nbsp; 
                Placebo / Elagolix 250 mg
              </th>
                                          <th class="header3 brt bold_participant_color" style="max-width:20%; text-align:center;">
                              &nbsp; 
                Leuprorelin / Elagolix 150 mg
              </th>
                                          <th class="header3 brt bold_participant_color" style="max-width:20%; text-align:center;">
                              &nbsp; 
                Leuprorelin / Elagolix 250 mg
              </th>
                      </tr>
                
                
                          <tr>
                <th class="header3 brt bold_participant_color" style="text-align:left;">
                  STARTED&nbsp;                                  </th>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;0&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;42&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;43&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;0&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;20&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;21&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;22&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;22&nbsp;                  </td>
                              </tr>
              
                            
                          <tr>
                <th class="header3 brt bold_participant_color" style="text-align:left;">
                  COMPLETED&nbsp;                                  </th>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;0&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;38&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;41&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;0&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;19&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;21&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;20&nbsp;                  </td>
                                  <td class="header3 brt pale_participant_color" style="text-align:center;">
                    &nbsp;22&nbsp;                  </td>
                              </tr>
              
                            
                          <tr>
                <th class="header3 brt bold_participant_color" style="text-align:left;">
                  NOT COMPLETED&nbsp;                                  </th>
                                                      <td class="header3 brt pale_participant_color" style="text-align:center;">
                      &nbsp;0&nbsp;                    </td>
                                      <td class="header3 brt pale_participant_color" style="text-align:center;">
                      &nbsp;4&nbsp;                    </td>
                                      <td class="header3 brt pale_participant_color" style="text-align:center;">
                      &nbsp;2&nbsp;                    </td>
                                      <td class="header3 brt pale_participant_color" style="text-align:center;">
                      &nbsp;0&nbsp;                    </td>
                                      <td class="header3 brt pale_participant_color" style="text-align:center;">
                      &nbsp;1&nbsp;                    </td>
                                      <td class="header3 brt pale_participant_color" style="text-align:center;">
                      &nbsp;0&nbsp;                    </td>
                                      <td class="header3 brt pale_participant_color" style="text-align:center;">
                      &nbsp;2&nbsp;                    </td>
                                      <td class="header3 brt pale_participant_color" style="text-align:center;">
                      &nbsp;0&nbsp;                    </td>
                                                </tr>
                              <tr>
                  <td class="header3 br bold_participant_color" style="padding-left:2em;">
                    Non-compliance&nbsp;                                      </td>
                                                            <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 2&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                                      </tr>
                              <tr>
                  <td class="header3 br bold_participant_color" style="padding-left:2em;">
                    Withdrawal by Subject&nbsp;                                      </td>
                                                            <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 1&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 1&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                                      </tr>
                              <tr>
                  <td class="header3 br bold_participant_color" style="padding-left:2em;">
                    Lost to Follow-up&nbsp;                                      </td>
                                                            <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 1&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 1&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                                      </tr>
                              <tr>
                  <td class="header3 br bold_participant_color" style="padding-left:2em;">
                    Adverse Event&nbsp;                                      </td>
                                                            <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 1&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 1&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                                      </tr>
                              <tr>
                  <td class="header3 br bold_participant_color" style="padding-left:2em;">
                    Sponsor Decision&nbsp;                                      </td>
                                                            <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 1&nbsp;                      </td>
                                          <td class="header3 br pale_participant_color" style="text-align:center;">
                        &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; 0&nbsp;                      </td>
                                                      </tr>
                                            </tbody></table>
      
                <br>
        
              </div>
</div>
  
<!-- baseline section -->
<br>
<div class="indent1">

  <br>
  <img src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20Versus%20Placebo%20or%20Leuprorelin%20Acetate%20in%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/triangle.gif" alt=""><span class="header2">&nbsp; Baseline Characteristics</span>

  <a name="base" id="base"></a>
  <div class="header3 indent2">

        <div style="margin-top:1.0ex;">
      <a title="Hide baseline characteristics" href="https://clinicaltrials.gov/ct2/show/results/NCT00797225?sect=X0256#base">
        <img style="float:left" src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20Versus%20Placebo%20or%20Leuprorelin%20Acetate%20in%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/minus.gif" alt="" border="0"> &nbsp; Hide Baseline Characteristics
      </a>
    </div>

    <br>
    <span class="header3">Population Description</span>
    <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
      <tbody><tr>
        <th class="header3 bold_baseline_color" style="text-align:left;">
          Explanation of how the number of participants for analysis was determined.
          Includes whether analysis was per protocol, intention to treat, or another method.
          Also provides relevant details such as imputation technique, as appropriate.
        </th>
      </tr>
      <tr>
        <td class="body3 pale_baseline_color" style="vertical-align:top;">
                      No text entered.
                  </td>
      </tr>
    </tbody></table>

    <br>
    
            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_baseline_color">&nbsp;</th>
      <th class="header3 bold_baseline_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_baseline_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_baseline_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and placebo intramuscular injection once a month for 12 weeks. At 
the end of 12 weeks participants were re-randomized to receive one of 
the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_baseline_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_baseline_color" style="vertical-align:top;">
                          Participants received elagolix 150 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 150 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_baseline_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 250 mg</th>
          <td class="body3 pale_baseline_color" style="vertical-align:top;">
                          Participants received elagolix 250 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 250 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_baseline_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Leuprorelin</th>
          <td class="body3 pale_baseline_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and leuprorelin acetate 1-month depot 3.75 mg intramuscular 
injection once a month for 12 weeks. At the end of 12 weeks participants
 were re-randomized to receive one of the two doses of elagolix (150 mg 
or 250 mg) for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_baseline_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Total</th>
          <td class="body3 pale_baseline_color" style="vertical-align:top;">
                          Total of all reporting groups
                      </td>
        </tr>
      </tbody></table>
      
      <br>
            
          
          
    
      <span class="header3">Baseline Measures</span>
      <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0">
        <tbody><tr>
          <th class="brt bold_baseline_color" style="max-width:50%">&nbsp;</th>
                      <th class="header3 brt bold_baseline_color" style="max-width:20%;text-align:center;">
              &nbsp;Placebo&nbsp;
            </th>
                      <th class="header3 brt bold_baseline_color" style="max-width:20%;text-align:center;">
              &nbsp;Elagolix 150 mg&nbsp;
            </th>
                      <th class="header3 brt bold_baseline_color" style="max-width:20%;text-align:center;">
              &nbsp;Elagolix 250 mg&nbsp;
            </th>
                      <th class="header3 brt bold_baseline_color" style="max-width:20%;text-align:center;">
              &nbsp;Leuprorelin&nbsp;
            </th>
                      <th class="header3 brt bold_baseline_color" style="max-width:20%;text-align:center;">
              &nbsp;Total&nbsp;
            </th>
                  </tr>
    
            
                      <tr>
              <th class="header3 brt bold_baseline_color" style="text-align:left;">
                Overall Participants Analyzed&nbsp;                <br><span class="body3">[Units:&nbsp;Participants]<br></span>               </th>
                              <td class="header3 brt pale_baseline_color" style="text-align:center;">
                                      &nbsp;43&nbsp;                                  </td>
                              <td class="header3 brt pale_baseline_color" style="text-align:center;">
                                      &nbsp;43&nbsp;                                  </td>
                              <td class="header3 brt pale_baseline_color" style="text-align:center;">
                                      &nbsp;44&nbsp;                                  </td>
                              <td class="header3 brt pale_baseline_color" style="text-align:center;">
                                      &nbsp;44&nbsp;                                  </td>
                              <td class="header3 brt pale_baseline_color" style="text-align:center;">
                                      &nbsp;174&nbsp;                                  </td>
                          </tr>
            
              
                                    <tr>
                <td class="brt" colspan="1000" style="padding:2px 2px;">
              </td></tr>
                                  
                      <tr>
              <th class="header3 brt bold_baseline_color" style="text-align:left;">
                Age&nbsp;                <br><span class="body3">[Units:&nbsp;Years]<br>Mean (Standard Deviation)</span>               </th>
                              <td class="header3 brt pale_baseline_color" style="text-align:center;">
                                                            
&nbsp;31.4&nbsp;&nbsp;(0.8)&nbsp;                                       
               </td>
                              <td class="header3 brt pale_baseline_color" style="text-align:center;">
                                                            
&nbsp;32.1&nbsp;&nbsp;(0.9)&nbsp;                                       
               </td>
                              <td class="header3 brt pale_baseline_color" style="text-align:center;">
                                                            
&nbsp;31.7&nbsp;&nbsp;(1.0)&nbsp;                                       
               </td>
                              <td class="header3 brt pale_baseline_color" style="text-align:center;">
                                                            
&nbsp;31.4&nbsp;&nbsp;(0.7)&nbsp;                                       
               </td>
                              <td class="header3 brt pale_baseline_color" style="text-align:center;">
                                                            
&nbsp;31.7&nbsp;&nbsp;(0.4)&nbsp;                                       
               </td>
                          </tr>
            
              
                                    <tr>
                <td class="brt" colspan="1000" style="padding:2px 2px;">
              </td></tr>
                                  
                      <tr>
              <th class="header3 brt bold_baseline_color" style="text-align:left;">
                Sex: Female, Male&nbsp;                <br><span class="body3">[Units:&nbsp;Participants]<br>Count of Participants</span>               </th>
                                                <td class="brt pale_baseline_color">&nbsp;</td>
                                  <td class="brt pale_baseline_color">&nbsp;</td>
                                  <td class="brt pale_baseline_color">&nbsp;</td>
                                  <td class="brt pale_baseline_color">&nbsp;</td>
                                  <td class="brt pale_baseline_color">&nbsp;</td>
                                          </tr>
                          <tr>
                <td class="header3 br bold_baseline_color" style="padding-left:2em;">
                  Female&nbsp;                                  </td>
                                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 43<span class="body3"> 100.0%</span>&nbsp;                                          </td>
                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 43<span class="body3"> 100.0%</span>&nbsp;                                          </td>
                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 44<span class="body3"> 100.0%</span>&nbsp;                                          </td>
                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 44<span class="body3"> 100.0%</span>&nbsp;                                          </td>
                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 174<span class="body3"> 100.0%</span>&nbsp;                                          </td>
                                                </tr>
                                        <tr>
                <td class="header3 br bold_baseline_color" style="padding-left:2em;">
                  Male&nbsp;                                  </td>
                                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 0<span class="body3">   0.0%</span>&nbsp;                                          </td>
                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 0<span class="body3">   0.0%</span>&nbsp;                                          </td>
                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 0<span class="body3">   0.0%</span>&nbsp;                                          </td>
                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 0<span class="body3">   0.0%</span>&nbsp;                                          </td>
                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp; &nbsp; 0<span class="body3">   0.0%</span>&nbsp;                                          </td>
                                                </tr>
                                        
                                    <tr>
                <td class="brt" colspan="1000" style="padding:2px 2px;">
              </td></tr>
                                  
                      <tr>
              <th class="header3 brt bold_baseline_color" style="text-align:left;">
                Race/Ethnicity, Customized&nbsp;                <br><span class="body3">[Units:&nbsp;Participants]<br>Count of Participants</span>               </th>
                                                <td class="brt pale_baseline_color">&nbsp;</td>
                                  <td class="brt pale_baseline_color">&nbsp;</td>
                                  <td class="brt pale_baseline_color">&nbsp;</td>
                                  <td class="brt pale_baseline_color">&nbsp;</td>
                                  <td class="brt pale_baseline_color">&nbsp;</td>
                                          </tr>
                          <tr>
                <td class="header3 br bold_baseline_color" style="padding-left:2em;">
                  White&nbsp;                                  </td>
                                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp;43&nbsp;                                          </td>
                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp;43&nbsp;                                          </td>
                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp;44&nbsp;                                          </td>
                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp;44&nbsp;                                          </td>
                                      <td class="header3 br pale_baseline_color" style="text-align:center;">
                                              &nbsp;174&nbsp;                                          </td>
                                                </tr>
                                        
                                    <tr>
                <td class="brt" colspan="1000" style="padding:2px 2px;">
              </td></tr>
                                    </tbody></table>
      
      
      
        </div>
</div>
  
<!-- outcome measures section -->
<br>
<div class="indent1">

  <br>
  <img src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20Versus%20Placebo%20or%20Leuprorelin%20Acetate%20in%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/triangle.gif" alt=""><span class="header2">&nbsp; Outcome Measures</span>
  <a name="all" id="all"></a>
  <div class="header3 indent2">

            <div style="margin-top:1.0ex;">
      <a title="Hide all outcome measures" href="https://clinicaltrials.gov/ct2/show/results/NCT00797225?sect=X0156#all">
        <img style="float:left" src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20Versus%20Placebo%20or%20Leuprorelin%20Acetate%20in%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/minus.gif" alt="" border="0"> &nbsp; Hide All Outcome Measures
      </a>
    </div>
    
                  <a name="outcome1" id="outcome1"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">1.&nbsp; Primary: &nbsp; </td>
            <td>Change From Baseline in the Monthly Mean Numerical 
Rating Score (NRS) for Endometriosis Pain &nbsp; [ Time Frame: Baseline 
and Weeks 4, 8, and 12 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Primary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Change From Baseline in the Monthly Mean Numerical Rating Score (NRS) for Endometriosis Pain</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">The
 NRS is an 11-point scale used to measure endometriosis pain and was 
completed at approximately the same time each day using an electronic 
diary (e-Diary). Participants were instructed to select a single number 
between 0 (No pain) and 10 (Worst pain ever) that best described their 
endometriosis pain at its worst over the past day.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">The monthly mean NRS is the average of the daily values reported during the 4 weeks prior to each visit.</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and Weeks 4, 8, and 12 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 1 evaluable 
e-Diary report following randomization (intent-to-treat population). The
 analysis includes participants with non-missing data at each time 
point.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and placebo intramuscular injection once a month for 12 weeks. At 
the end of 12 weeks participants were re-randomized to receive one of 
the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 150 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 150 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 250 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 250 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 250 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Leuprorelin</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and leuprorelin acetate 1-month depot 3.75 mg intramuscular 
injection once a month for 12 weeks. At the end of 12 weeks participants
 were re-randomized to receive one of the two doses of elagolix (150 mg 
or 250 mg) for 12 weeks.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 250 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Leuprorelin&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;43&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;43&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;44&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;44&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Change From Baseline in the Monthly Mean 
Numerical Rating Score (NRS) for Endometriosis Pain&nbsp;               
         <br><span class="body3">[Units:&nbsp;Units&nbsp;on&nbsp;a&nbsp;scale]<br>Least Squares Mean (Standard Error)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 4&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 4&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.35&nbsp;&nbsp;(0.17)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.84&nbsp;&nbsp;(0.17)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-1.00&nbsp;&nbsp;(0.17)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.94&nbsp;&nbsp;(0.17)&nbsp; 
                                                                        
                             </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 8&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 8&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.93&nbsp;&nbsp;(0.20)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-1.25&nbsp;&nbsp;(0.20)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-1.57&nbsp;&nbsp;(0.20)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-1.55&nbsp;&nbsp;(0.20)&nbsp; 
                                                                        
                             </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 12&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;42&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;42&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 12&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-1.22&nbsp;&nbsp;(0.21)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-1.34&nbsp;&nbsp;(0.21)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-1.47&nbsp;&nbsp;(0.21)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-1.81&nbsp;&nbsp;(0.20)&nbsp; 
                                                                        
                             </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                                                <br>
                  <span class="header3">Statistical Analysis 1 for Change From Baseline in the Monthly Mean Numerical Rating Score (NRS) for Endometriosis Pain</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Elagolix 150 mg</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0464</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.49</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.98 to -0.01</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.25)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
4. The change from baseline in monthly mean values of the NRS for 
overall endometriosis-associated pelvic pain was analyzed using a 
mixed-effects repeated measures analysis of covariance model. The model 
included fixed effects for treatment, time, the treatment-by-time 
interaction, a random effect for participant, the baseline-by-time 
interaction and the baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 2 for Change From Baseline in the Monthly Mean Numerical Rating Score (NRS) for Endometriosis Pain</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Elagolix 250 mg</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0080</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.65</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-1.13 to -0.17</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.24)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
4. The change from baseline in monthly mean values of the NRS for 
overall endometriosis-associated pelvic pain was analyzed using a 
mixed-effects repeated measures analysis of covariance model. The model 
included fixed effects for treatment, time, the treatment-by-time 
interaction, a random effect for participant, the baseline-by-time 
interaction and the baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 3 for Change From Baseline in the Monthly Mean Numerical Rating Score (NRS) for Endometriosis Pain</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Leuprorelin</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0159</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.59</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-1.08 to -0.11</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.24)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
4. The change from baseline in monthly mean values of the NRS for 
overall endometriosis-associated pelvic pain was analyzed using a 
mixed-effects repeated measures analysis of covariance model. The model 
included fixed effects for treatment, time, the treatment-by-time 
interaction, a random effect for participant, the baseline-by-time 
interaction and the baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 4 for Change From Baseline in the Monthly Mean Numerical Rating Score (NRS) for Endometriosis Pain</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Elagolix 150 mg</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.2563</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.33</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.89 to 0.24</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.29)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
8. The change from baseline in monthly mean values of the NRS for 
overall endometriosis-associated pelvic pain was analyzed using a 
mixed-effects repeated measures analysis of covariance model. The model 
included fixed effects for treatment, time, the treatment-by-time 
interaction, a random effect for participant, the baseline-by-time 
interaction and the baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 5 for Change From Baseline in the Monthly Mean Numerical Rating Score (NRS) for Endometriosis Pain</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Elagolix 250 mg</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0239</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.65</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-1.21 to -0.09</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.28)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
8. The change from baseline in monthly mean values of the NRS for 
overall endometriosis-associated pelvic pain was analyzed using a 
mixed-effects repeated measures analysis of covariance model. The model 
included fixed effects for treatment, time, the treatment-by-time 
interaction, a random effect for participant, the baseline-by-time 
interaction and the baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 6 for Change From Baseline in the Monthly Mean Numerical Rating Score (NRS) for Endometriosis Pain</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Leuprorelin</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0280</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.63</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-1.19 to -0.07</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.28)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
8. The change from baseline in monthly mean values of the NRS for 
overall endometriosis-associated pelvic pain was analyzed using a 
mixed-effects repeated measures analysis of covariance model. The model 
included fixed effects for treatment, time, the treatment-by-time 
interaction, a random effect for participant, the baseline-by-time 
interaction and the baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 7 for Change From Baseline in the Monthly Mean Numerical Rating Score (NRS) for Endometriosis Pain</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Elagolix 150 mg</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.6904</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.12</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.70 to 0.46</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.29)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
12. The change from baseline in monthly mean values of the NRS for 
overall endometriosis-associated pelvic pain was analyzed using a 
mixed-effects repeated measures analysis of covariance model. The model 
included fixed effects for treatment, time, the treatment-by-time 
interaction, a random effect for participant, the baseline-by-time 
interaction and the baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 8 for Change From Baseline in the Monthly Mean Numerical Rating Score (NRS) for Endometriosis Pain</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Elagolix 250 mg</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.4022</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.25</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.83 to 0.33</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.29)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
12. The change from baseline in monthly mean values of the NRS for 
overall endometriosis-associated pelvic pain was analyzed using a 
mixed-effects repeated measures analysis of covariance model. The model 
included fixed effects for treatment, time, the treatment-by-time 
interaction, a random effect for participant, the baseline-by-time 
interaction and the baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 9 for Change From Baseline in the Monthly Mean Numerical Rating Score (NRS) for Endometriosis Pain</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Leuprorelin</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0451</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.59</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-1.17 to -0.01</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.29)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
12. The change from baseline in monthly mean values of the NRS for 
overall endometriosis-associated pelvic pain was analyzed using a 
mixed-effects repeated measures analysis of covariance model. The model 
included fixed effects for treatment, time, the treatment-by-time 
interaction, a random effect for participant, the baseline-by-time 
interaction and the baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                            <br>
              <br>
                              </div>
              <a name="outcome2" id="outcome2"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">2.&nbsp; Secondary: &nbsp; </td>
            <td>Change From Baseline in the Monthly Peak Numerical 
Rating Score (NRS) for Endometriosis Pain &nbsp; [ Time Frame: Baseline 
and Weeks 4, 8, and 12 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Change From Baseline in the Monthly Peak Numerical Rating Score (NRS) for Endometriosis Pain</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">The
 NRS is an 11-point scale used to measure endometriosis pain and was 
completed at approximately the same time each day using an electronic 
diary (e-Diary). Participants were instructed to select a single number 
between 0 (No pain) and 10 (Worst pain ever) that best described their 
endometriosis pain at its worst over the past day.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">The monthly peak NRS is the maximum of the daily values reported during the 4 weeks prior to each visit.</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and Weeks 4, 8, and 12 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 1 evaluable 
e-Diary report following randomization (intent-to-treat population). The
 analysis includes participants with non-missing data at each time 
point.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and placebo intramuscular injection once a month for 12 weeks. At 
the end of 12 weeks participants were re-randomized to receive one of 
the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 150 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 150 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 250 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 250 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 250 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Leuprorelin</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and leuprorelin acetate 1-month depot 3.75 mg intramuscular 
injection once a month for 12 weeks. At the end of 12 weeks participants
 were re-randomized to receive one of the two doses of elagolix (150 mg 
or 250 mg) for 12 weeks.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 250 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Leuprorelin&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;43&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;43&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;44&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;44&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Change From Baseline in the Monthly Peak 
Numerical Rating Score (NRS) for Endometriosis Pain&nbsp;               
         <br><span class="body3">[Units:&nbsp;Units&nbsp;on&nbsp;a&nbsp;scale]<br>Least Squares Mean (Standard Error)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 4&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 4&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.20&nbsp;&nbsp;(0.34)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-1.82&nbsp;&nbsp;(0.34)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-1.83&nbsp;&nbsp;(0.33)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-1.48&nbsp;&nbsp;(0.33)&nbsp; 
                                                                        
                             </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 8&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 8&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.89&nbsp;&nbsp;(0.34)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-2.23&nbsp;&nbsp;(0.34)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-2.96&nbsp;&nbsp;(0.33)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-3.62&nbsp;&nbsp;(0.33)&nbsp; 
                                                                        
                             </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 12&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;42&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;42&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 12&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-1.67&nbsp;&nbsp;(0.34)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-2.62&nbsp;&nbsp;(0.34)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-3.05&nbsp;&nbsp;(0.34)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-3.99&nbsp;&nbsp;(0.33)&nbsp; 
                                                                        
                             </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                                                <br>
                  <span class="header3">Statistical Analysis 1 for Change From Baseline in the Monthly Peak Numerical Rating Score (NRS) for Endometriosis Pain</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Elagolix 150 mg</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0007</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-1.62</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-2.56 to -0.69</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.48)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
4. The change from baseline in monthly peak value of the NRS for overall
 endometriosis-associated pelvic pain was analyzed using a mixed-effects
 repeated measures analysis of covariance model. The model included 
fixed effects for treatment, time, the treatment-by-time interaction, a 
random effect for participant, the baseline-by-time interaction and the 
baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 2 for Change From Baseline in the Monthly Peak Numerical Rating Score (NRS) for Endometriosis Pain</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Elagolix 250 mg</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0006</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-1.63</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-2.56 to -0.70</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.47)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
4. The change from baseline in monthly peak value of the NRS for overall
 endometriosis-associated pelvic pain was analyzed using a mixed-effects
 repeated measures analysis of covariance model. The model included 
fixed effects for treatment, time, the treatment-by-time interaction, a 
random effect for participant, the baseline-by-time interaction and the 
baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 3 for Change From Baseline in the Monthly Peak Numerical Rating Score (NRS) for Endometriosis Pain</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Leuprorelin</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0073</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-1.28</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-2.21 to -0.35</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.47)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
4. The change from baseline in monthly peak value of the NRS for overall
 endometriosis-associated pelvic pain was analyzed using a mixed-effects
 repeated measures analysis of covariance model. The model included 
fixed effects for treatment, time, the treatment-by-time interaction, a 
random effect for participant, the baseline-by-time interaction and the 
baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 4 for Change From Baseline in the Monthly Peak Numerical Rating Score (NRS) for Endometriosis Pain</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Elagolix 150 mg</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0054</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-1.34</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-2.28 to -0.40</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.48)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
8. The change from baseline in monthly peak value of the NRS for overall
 endometriosis-associated pelvic pain was analyzed using a mixed-effects
 repeated measures analysis of covariance model. The model included 
fixed effects for treatment, time, the treatment-by-time interaction, a 
random effect for participant, the baseline-by-time interaction and the 
baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 5 for Change From Baseline in the Monthly Peak Numerical Rating Score (NRS) for Endometriosis Pain</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Elagolix 250 mg</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">&lt; 0.0001</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-2.07</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-3.01 to -1.12</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.48)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
8. The change from baseline in monthly peak value of the NRS for overall
 endometriosis-associated pelvic pain was analyzed using a mixed-effects
 repeated measures analysis of covariance model. The model included 
fixed effects for treatment, time, the treatment-by-time interaction, a 
random effect for participant, the baseline-by-time interaction and the 
baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 6 for Change From Baseline in the Monthly Peak Numerical Rating Score (NRS) for Endometriosis Pain</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Leuprorelin</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">&lt; 0.0001</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-2.73</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-3.67 to -1.79</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.48)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
8. The change from baseline in monthly peak value of the NRS for overall
 endometriosis-associated pelvic pain was analyzed using a mixed-effects
 repeated measures analysis of covariance model. The model included 
fixed effects for treatment, time, the treatment-by-time interaction, a 
random effect for participant, the baseline-by-time interaction and the 
baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 7 for Change From Baseline in the Monthly Peak Numerical Rating Score (NRS) for Endometriosis Pain</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Elagolix 150 mg</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0509</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.95</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-1.89 to 0.00</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.48)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
12. The change from baseline in monthly peak value of the NRS for 
overall endometriosis-associated pelvic pain was analyzed using a 
mixed-effects repeated measures analysis of covariance model. The model 
included fixed effects for treatment, time, the treatment-by-time 
interaction, a random effect for participant, the baseline-by-time 
interaction and the baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 8 for Change From Baseline in the Monthly Peak Numerical Rating Score (NRS) for Endometriosis Pain</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Elagolix 250 mg</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0046</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-1.38</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-2.33 to -0.43</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.48)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
12. The change from baseline in monthly peak value of the NRS for 
overall endometriosis-associated pelvic pain was analyzed using a 
mixed-effects repeated measures analysis of covariance model. The model 
included fixed effects for treatment, time, the treatment-by-time 
interaction, a random effect for participant, the baseline-by-time 
interaction and the baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 9 for Change From Baseline in the Monthly Peak Numerical Rating Score (NRS) for Endometriosis Pain</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Leuprorelin</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">&lt; 0.0001</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-2.32</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-3.26 to -1.38</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.48)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
12. The change from baseline in monthly peak value of the NRS for 
overall endometriosis-associated pelvic pain was analyzed using a 
mixed-effects repeated measures analysis of covariance model. The model 
included fixed effects for treatment, time, the treatment-by-time 
interaction, a random effect for participant, the baseline-by-time 
interaction and the baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                            <br>
              <br>
                              </div>
              <a name="outcome3" id="outcome3"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">3.&nbsp; Secondary: &nbsp; </td>
            <td>Change From Baseline in the Monthly Mean Non-menstrual Pelvic Pain Score &nbsp; [ Time Frame: Baseline and Weeks 4, 8, and 12 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Change From Baseline in the Monthly Mean Non-menstrual Pelvic Pain Score</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">Participants
 assessed their pelvic pain not related to menses and its impact on 
their daily activities at approximately the same time every day in an 
e-Diary according to the following response options:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">0 = No pelvic pain</li>
    <li style="margin-top:0.7ex;">1 = Mild pelvic pain; subject could not do some of the things she usually does</li>
    <li style="margin-top:0.7ex;">2 = Moderate pelvic pain; subject could not do many of the things she usually does</li>
    <li style="margin-top:0.7ex;">3 = Severe pelvic pain; subject could not do most or all of the things she usually does.</li>
  </ul>
  <p style="margin-top:0ex; margin-bottom:1ex;">The monthly mean 
non-menstrual pelvic pain score is the average of the daily values 
reported during the 4 weeks prior to each visit.</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and Weeks 4, 8, and 12 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 1 evaluable 
e-Diary report following randomization (intent-to-treat population). The
 analysis includes participants with non-missing data at each time 
point.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and placebo intramuscular injection once a month for 12 weeks. At 
the end of 12 weeks participants were re-randomized to receive one of 
the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 150 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 150 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 250 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 250 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 250 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Leuprorelin</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and leuprorelin acetate 1-month depot 3.75 mg intramuscular 
injection once a month for 12 weeks. At the end of 12 weeks participants
 were re-randomized to receive one of the two doses of elagolix (150 mg 
or 250 mg) for 12 weeks.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 250 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Leuprorelin&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;43&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;43&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;44&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;44&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Change From Baseline in the Monthly Mean Non-menstrual Pelvic Pain Score&nbsp;                        <br><span class="body3">[Units:&nbsp;Units&nbsp;on&nbsp;a&nbsp;scale]<br>Least Squares Mean (Standard Error)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 4&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 4&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.05&nbsp;&nbsp;(0.06)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.22&nbsp;&nbsp;(0.06)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.21&nbsp;&nbsp;(0.06)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.27&nbsp;&nbsp;(0.06)&nbsp; 
                                                                        
                             </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 8&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 8&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.18&nbsp;&nbsp;(0.06)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.34&nbsp;&nbsp;(0.06)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.36&nbsp;&nbsp;(0.06)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.46&nbsp;&nbsp;(0.06)&nbsp; 
                                                                        
                             </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 12&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;42&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;42&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 12&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.30&nbsp;&nbsp;(0.06)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.35&nbsp;&nbsp;(0.06)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.34&nbsp;&nbsp;(0.06)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.55&nbsp;&nbsp;(0.06)&nbsp; 
                                                                        
                             </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                                                <br>
                  <span class="header3">Statistical Analysis 1 for Change From Baseline in the Monthly Mean Non-menstrual Pelvic Pain Score</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Elagolix 150 mg</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0453</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.16</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.33 to 0.00</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.08)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
4. The change from baseline in monthly mean non-menstrual pelvic pain 
scores was analyzed using a mixed-effects repeated measures analysis of 
covariance model. The model included fixed effects for treatment, time, 
the treatment-by-time interaction, a random effect for participant, the 
baseline-by-time interaction and the baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 2 for Change From Baseline in the Monthly Mean Non-menstrual Pelvic Pain Score</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Elagolix 250 mg</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0609</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.15</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.31 to 0.01</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.08)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
4. The change from baseline in monthly mean non-menstrual pelvic pain 
scores was analyzed using a mixed-effects repeated measures analysis of 
covariance model. The model included fixed effects for treatment, time, 
the treatment-by-time interaction, a random effect for participant, the 
baseline-by-time interaction and the baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 3 for Change From Baseline in the Monthly Mean Non-menstrual Pelvic Pain Score</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Leuprorelin</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0069</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.22</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.38 to -0.06</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.08)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
4. The change from baseline in monthly mean non-menstrual pelvic pain 
scores was analyzed using a mixed-effects repeated measures analysis of 
covariance model. The model included fixed effects for treatment, time, 
the treatment-by-time interaction, a random effect for participant, the 
baseline-by-time interaction and the baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 4 for Change From Baseline in the Monthly Mean Non-menstrual Pelvic Pain Score</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Elagolix 150 mg</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model]</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0556</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.16</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.32 to 0.00</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.08)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
8. The change from baseline in monthly mean non-menstrual pelvic pain 
scores was analyzed using a mixed-effects repeated measures analysis of 
covariance model. The model included fixed effects for treatment, time, 
the treatment-by-time interaction, a random effect for participant, the 
baseline-by-time interaction and the baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 5 for Change From Baseline in the Monthly Mean Non-menstrual Pelvic Pain Score</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Elagolix 250 mg</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0387</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.17</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.33 to -0.01</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.08)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
8. The change from baseline in monthly mean non-menstrual pelvic pain 
scores was analyzed using a mixed-effects repeated measures analysis of 
covariance model. The model included fixed effects for treatment, time, 
the treatment-by-time interaction, a random effect for participant, the 
baseline-by-time interaction and the baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 6 for Change From Baseline in the Monthly Mean Non-menstrual Pelvic Pain Score</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Leuprorelin</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0008</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.28</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.44 to -0.12</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.08)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
8. The change from baseline in monthly mean non-menstrual pelvic pain 
scores was analyzed using a mixed-effects repeated measures analysis of 
covariance model. The model included fixed effects for treatment, time, 
the treatment-by-time interaction, a random effect for participant, the 
baseline-by-time interaction and the baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 7 for Change From Baseline in the Monthly Mean Non-menstrual Pelvic Pain Score</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Elagolix 150 mg</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.5879</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.04</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.21 to 0.12</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.08)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
12. The change from baseline in monthly mean non-menstrual pelvic pain 
scores was analyzed using a mixed-effects repeated measures analysis of 
covariance model. The model included fixed effects for treatment, time, 
the treatment-by-time interaction, a random effect for participant, the 
baseline-by-time interaction and the baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 8 for Change From Baseline in the Monthly Mean Non-menstrual Pelvic Pain Score</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Elagolix 250 mg</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.6122</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.04</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.20 to 0.12</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.08)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
12. The change from baseline in monthly mean non-menstrual pelvic pain 
scores was analyzed using a mixed-effects repeated measures analysis of 
covariance model. The model included fixed effects for treatment, time, 
the treatment-by-time interaction, a random effect for participant, the 
baseline-by-time interaction and the baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 9 for Change From Baseline in the Monthly Mean Non-menstrual Pelvic Pain Score</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Leuprorelin</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0023</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.25</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.41 to -0.09</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.08)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
12. The change from baseline in monthly mean non-menstrual pelvic pain 
scores was analyzed using a mixed-effects repeated measures analysis of 
covariance model. The model included fixed effects for treatment, time, 
the treatment-by-time interaction, a random effect for participant, the 
baseline-by-time interaction and the baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                            <br>
              <br>
                              </div>
              <a name="outcome4" id="outcome4"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">4.&nbsp; Secondary: &nbsp; </td>
            <td>Change From Baseline in the Monthly Mean Dysmenorrhea Score &nbsp; [ Time Frame: Baseline and Weeks 4, 8, and 12 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Change From Baseline in the Monthly Mean Dysmenorrhea Score</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">Participants
 assessed dysmenorrhea (pain during menstruation) and its impact on 
their daily activities at approximately the same time each day of their 
period in an e-Diary according to the following response options:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">Subject is not having her period</li>
    <li style="margin-top:0.7ex;">0 = No pain related to period</li>
    <li style="margin-top:0.7ex;">1 = Mild pain related to period; subject could not do some of the things she usually does</li>
    <li style="margin-top:0.7ex;">2 = Moderate pain related to period; subject could not do many of the things she usually does</li>
    <li style="margin-top:0.7ex;">3 = Severe pain related to period; subject could not do most of or all of the things she usually does.</li>
  </ul>
  <p style="margin-top:0ex; margin-bottom:1ex;">The monthly mean dysmenorrhea score is the average of the daily values reported during the 4 weeks prior to each visit.</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and Weeks 4, 8, and 12 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 1 evaluable 
e-Diary report following randomization (intent-to-treat population). The
 analysis includes participants with non-missing data at each time 
point.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and placebo intramuscular injection once a month for 12 weeks. At 
the end of 12 weeks participants were re-randomized to receive one of 
the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 150 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 150 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 250 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 250 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 250 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Leuprorelin</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and leuprorelin acetate 1-month depot 3.75 mg intramuscular 
injection once a month for 12 weeks. At the end of 12 weeks participants
 were re-randomized to receive one of the two doses of elagolix (150 mg 
or 250 mg) for 12 weeks.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 250 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Leuprorelin&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;43&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;43&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;44&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;44&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Change From Baseline in the Monthly Mean Dysmenorrhea Score&nbsp;                        <br><span class="body3">[Units:&nbsp;Units&nbsp;on&nbsp;a&nbsp;scale]<br>Least Squares Mean (Standard Error)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 4&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 4&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.17&nbsp;&nbsp;(0.08)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.64&nbsp;&nbsp;(0.08)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.67&nbsp;&nbsp;(0.08)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.65&nbsp;&nbsp;(0.08)&nbsp; 
                                                                        
                             </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 8&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 8&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.40&nbsp;&nbsp;(0.08)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.86&nbsp;&nbsp;(0.08)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-1.04&nbsp;&nbsp;(0.08)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-1.22&nbsp;&nbsp;(0.08)&nbsp; 
                                                                        
                             </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 12&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;42&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;42&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 12&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.35&nbsp;&nbsp;(0.08)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.76&nbsp;&nbsp;(0.08)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.87&nbsp;&nbsp;(0.08)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-1.14&nbsp;&nbsp;(0.08)&nbsp; 
                                                                        
                             </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                                                <br>
                  <span class="header3">Statistical Analysis 1 for Change From Baseline in the Monthly Mean Dysmenorrhea Score</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Elagolix 150 mg</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">&lt; 0.0001</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.47</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.69 to -0.24</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.12)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
4. The change from baseline in monthly mean dysmenorrhea scores was 
analyzed using a mixed-effects repeated measures analysis of covariance 
model. The model included fixed effects for treatment, time, the 
treatment-by-time interaction, a random effect for participant, the 
baseline-by-time interaction and the baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 2 for Change From Baseline in the Monthly Mean Dysmenorrhea Score</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Elagolix 250 mg</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">&lt; 0.0001</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.50</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.73 to -0.27</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.12)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
4. The change from baseline in monthly mean dysmenorrhea scores was 
analyzed using a mixed-effects repeated measures analysis of covariance 
model. The model included fixed effects for treatment, time, the 
treatment-by-time interaction, a random effect for participant, the 
baseline-by-time interaction and the baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 3 for Change From Baseline in the Monthly Mean Dysmenorrhea Score</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Leuprorelin</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">&lt; 0.0001</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.48</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.71 to -0.25</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.12)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
4. The change from baseline in monthly mean dysmenorrhea scores was 
analyzed using a mixed-effects repeated measures analysis of covariance 
model. The model included fixed effects for treatment, time, the 
treatment-by-time interaction, a random effect for participant, the 
baseline-by-time interaction and the baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 4 for Change From Baseline in the Monthly Mean Dysmenorrhea Score</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Elagolix 150 mg</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">&lt; 0.0001</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.46</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.69 to -0.23</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.12)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
8. The change from baseline in monthly mean dysmenorrhea scores was 
analyzed using a mixed-effects repeated measures analysis of covariance 
model. The model included fixed effects for treatment, time, the 
treatment-by-time interaction, a random effect for participant, the 
baseline-by-time interaction and the baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 5 for Change From Baseline in the Monthly Mean Dysmenorrhea Score</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Elagolix 250 mg</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">&lt; 0.0001</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.64</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.87 to -0.40</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.12)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
8. The change from baseline in monthly mean dysmenorrhea scores was 
analyzed using a mixed-effects repeated measures analysis of covariance 
model. The model included fixed effects for treatment, time, the 
treatment-by-time interaction, a random effect for participant, the 
baseline-by-time interaction and the baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 6 for Change From Baseline in the Monthly Mean Dysmenorrhea Score</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Leuprorelin</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">&lt; 0.0001</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.82</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-1.04 to -0.59</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.12)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
8. The change from baseline in monthly mean dysmenorrhea scores was 
analyzed using a mixed-effects repeated measures analysis of covariance 
model. The model included fixed effects for treatment, time, the 
treatment-by-time interaction, a random effect for participant, the 
baseline-by-time interaction and the baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 7 for Change From Baseline in the Monthly Mean Dysmenorrhea Score</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Elagolix 150 mg</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0005</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.41</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.65 to -0.18</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.12)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
12. The change from baseline in monthly mean dysmenorrhea scores was 
analyzed using a mixed-effects repeated measures analysis of covariance 
model. The model included fixed effects for treatment, time, the 
treatment-by-time interaction, a random effect for participant, the 
baseline-by-time interaction and the baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 8 for Change From Baseline in the Monthly Mean Dysmenorrhea Score</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Elagolix 250 mg</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">&lt; 0.0001</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.52</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.76 to -0.29</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.12)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
12. The change from baseline in monthly mean dysmenorrhea scores was 
analyzed using a mixed-effects repeated measures analysis of covariance 
model. The model included fixed effects for treatment, time, the 
treatment-by-time interaction, a random effect for participant, the 
baseline-by-time interaction and the baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 9 for Change From Baseline in the Monthly Mean Dysmenorrhea Score</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Leuprorelin</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">&lt; 0.0001</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.79</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-1.02 to -0.56</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.12)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
12. The change from baseline in monthly mean dysmenorrhea scores was 
analyzed using a mixed-effects repeated measures analysis of covariance 
model. The model included fixed effects for treatment, time, the 
treatment-by-time interaction, a random effect for participant, the 
baseline-by-time interaction and the baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                            <br>
              <br>
                              </div>
              <a name="outcome5" id="outcome5"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">5.&nbsp; Secondary: &nbsp; </td>
            <td>Change From Baseline in the Monthly Mean Sum of 
Dysmenorrhea and Non-menstrual Pelvic Pain Scores &nbsp; [ Time Frame: 
Baseline and Weeks 4, 8, and 12 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Change From Baseline in the Monthly Mean Sum of Dysmenorrhea and Non-menstrual Pelvic Pain Scores</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">Participants
 assessed dysmenorrhea and pelvic pain not related to menses and their 
impact on daily activities at approximately the same time every day on a
 4-point scale (0 = none, 1 = mild, 2 = moderate, and 3 = severe) in an 
e-Diary. The dysmenorrhea scale included an option for participants who 
were not having their period.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">The sum of the 
dysmenorrhea and non-menstrual pelvic pain scores on each day were 
calculated to create a daily total score. On days the participant was 
not having her period, the dysmenorrhea score was not defined; hence, 
the total score was equal to the non-menstrual pelvic pain score (range 0
 to 3). On days where the participant recorded menstruation the total 
score ranged from 0 to 6, where higher scores indicate more severe pain.
 The monthly mean sum of dysmenorrhea and non-menstrual pelvic pain 
scores is the average of the daily values reported during the 4 weeks 
prior to each visit.</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and Weeks 4, 8, and 12 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 1 evaluable 
e-Diary report following randomization (intent-to-treat population). The
 analysis includes participants with non-missing data at each time 
point.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and placebo intramuscular injection once a month for 12 weeks. At 
the end of 12 weeks participants were re-randomized to receive one of 
the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 150 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 150 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 250 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 250 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 250 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Leuprorelin</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and leuprorelin acetate 1-month depot 3.75 mg intramuscular 
injection once a month for 12 weeks. At the end of 12 weeks participants
 were re-randomized to receive one of the two doses of elagolix (150 mg 
or 250 mg) for 12 weeks.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 250 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Leuprorelin&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;43&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;43&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;44&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;44&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Change From Baseline in the Monthly Mean Sum of 
Dysmenorrhea and Non-menstrual Pelvic Pain Scores&nbsp;                 
       <br><span class="body3">[Units:&nbsp;Units&nbsp;on&nbsp;a&nbsp;scale]<br>Least Squares Mean (Standard Error)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 4&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 4&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.12&nbsp;&nbsp;(0.07)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.43&nbsp;&nbsp;(0.07)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.44&nbsp;&nbsp;(0.07)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.50&nbsp;&nbsp;(0.07)&nbsp; 
                                                                        
                             </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 8&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 8&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.24&nbsp;&nbsp;(0.07)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.58&nbsp;&nbsp;(0.07)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.67&nbsp;&nbsp;(0.07)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.78&nbsp;&nbsp;(0.07)&nbsp; 
                                                                        
                             </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 12&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;42&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;42&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 12&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.40&nbsp;&nbsp;(0.07)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.55&nbsp;&nbsp;(0.07)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.63&nbsp;&nbsp;(0.07)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.87&nbsp;&nbsp;(0.07)&nbsp; 
                                                                        
                             </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                                                <br>
                  <span class="header3">Statistical Analysis 1 for Change From Baseline in the Monthly Mean Sum of Dysmenorrhea and Non-menstrual Pelvic Pain Scores</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Elagolix 150 mg</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0011</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.32</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.51 to -0.13</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.10)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
4. The change from baseline in monthly mean sum of dysmenorrhea and 
non-menstrual pelvic pain scores was analyzed using a mixed-effects 
repeated measures analysis of covariance model. The model included fixed
 effects for treatment, time, the treatment-by-time interaction, a 
random effect for participant, the baseline-by-time interaction and the 
baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 2 for Change From Baseline in the Monthly Mean Sum of Dysmenorrhea and Non-menstrual Pelvic Pain Scores</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Elagolix 250 mg</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0010</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.32</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.51 to -0.13</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.10)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
4. The change from baseline in monthly mean sum of dysmenorrhea and 
non-menstrual pelvic pain scores was analyzed using a mixed-effects 
repeated measures analysis of covariance model. The model included fixed
 effects for treatment, time, the treatment-by-time interaction, a 
random effect for participant, the baseline-by-time interaction and the 
baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 3 for Change From Baseline in the Monthly Mean Sum of Dysmenorrhea and Non-menstrual Pelvic Pain Scores</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Leuprorelin</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">&lt; 0.0001</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.38</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.57 to -0.19</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.10)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
4. The change from baseline in monthly mean sum of dysmenorrhea and 
non-menstrual pelvic pain scores was analyzed using a mixed-effects 
repeated measures analysis of covariance model. The model included fixed
 effects for treatment, time, the treatment-by-time interaction, a 
random effect for participant, the baseline-by-time interaction and the 
baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 4 for Change From Baseline in the Monthly Mean Sum of Dysmenorrhea and Non-menstrual Pelvic Pain Scores</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Elagolix 150 mg</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0007</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">-0.33 <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.33</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.52 to -0.14</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.10)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
8. The change from baseline in monthly mean sum of dysmenorrhea and 
non-menstrual pelvic pain scores was analyzed using a mixed-effects 
repeated measures analysis of covariance model. The model included fixed
 effects for treatment, time, the treatment-by-time interaction, a 
random effect for participant, the baseline-by-time interaction and the 
baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 5 for Change From Baseline in the Monthly Mean Sum of Dysmenorrhea and Non-menstrual Pelvic Pain Scores</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Elagolix 250 mg</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">&lt; 0.0001</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.43</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.62 to -0.24</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.10)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
8. The change from baseline in monthly mean sum of dysmenorrhea and 
non-menstrual pelvic pain scores was analyzed using a mixed-effects 
repeated measures analysis of covariance model. The model included fixed
 effects for treatment, time, the treatment-by-time interaction, a 
random effect for participant, the baseline-by-time interaction and the 
baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 6 for Change From Baseline in the Monthly Mean Sum of Dysmenorrhea and Non-menstrual Pelvic Pain Scores</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Leuprorelin</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">&lt; 0.0001</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.54</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.73 to -0.35</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.10)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
8. The change from baseline in monthly mean sum of dysmenorrhea and 
non-menstrual pelvic pain scores was analyzed using a mixed-effects 
repeated measures analysis of covariance model. The model included fixed
 effects for treatment, time, the treatment-by-time interaction, a 
random effect for participant, the baseline-by-time interaction and the 
baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 7 for Change From Baseline in the Monthly Mean Sum of Dysmenorrhea and Non-menstrual Pelvic Pain Scores</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Elagolix 150 mg</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.1319</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.15</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.34 to 0.04</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.10)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
12. The change from baseline in monthly mean sum of dysmenorrhea and 
non-menstrual pelvic pain scores was analyzed using a mixed-effects 
repeated measures analysis of covariance model. The model included fixed
 effects for treatment, time, the treatment-by-time interaction, a 
random effect for participant, the baseline-by-time interaction and the 
baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 8 for Change From Baseline in the Monthly Mean Sum of Dysmenorrhea and Non-menstrual Pelvic Pain Scores</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Elagolix 250 mg</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">0.0222</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.22</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.42 to -0.03</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.10)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
12. The change from baseline in monthly mean sum of dysmenorrhea and 
non-menstrual pelvic pain scores was analyzed using a mixed-effects 
repeated measures analysis of covariance model. The model included fixed
 effects for treatment, time, the treatment-by-time interaction, a 
random effect for participant, the baseline-by-time interaction and the 
baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                  <br>
                  <span class="header3">Statistical Analysis 9 for Change From Baseline in the Monthly Mean Sum of Dysmenorrhea and Non-menstrual Pelvic Pain Scores</span>
                  <div class="indent2">

                                        <table class="data_table" style="margin-top:1.5ex;" cellspacing="0" cellpadding="5" border="1">
                      <tbody><tr>
                        <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Groups <span class="note_outcome_color"><sup>[1]</sup></span></th>
                        <td class="body3 pale_outcome_color">Placebo vs. Leuprorelin</td>
                                              </tr>

                                              <tr>
                          <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Test Type <span class="note_outcome_color"><sup>[2]</sup></span></th>
                          <td class="body3 pale_outcome_color">Superiority</td>
                                                  </tr>
                      
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Statistical Method <span class="note_outcome_color"><sup>[3]</sup></span></th>
                            <td class="body3 pale_outcome_color">Mixed-effects Repeated Measures Model</td>
                                                      </tr>
                        
                                                  <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">P Value <span class="note_outcome_color"><sup>[4]</sup></span></th>
                            <td class="body3 pale_outcome_color">&lt; 0.0001</td>
                                                      </tr>
                                              
                                                                        <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">LS Mean Difference <span class="note_outcome_color"><sup>[5]</sup></span></th>
                            <td class="body3 pale_outcome_color">-0.47</td>
                                                      </tr>
                                                                                                      <tr>
                              <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">95% Confidence Interval</th>
                              <td class="body3 pale_outcome_color">-0.66 to -0.28</td>
                            </tr>
                                                                                                    <tr>
                            <th class="header3 bold_outcome_color" style="text-align:left;white-space:nowrap;">Standard Error of the Mean</th>
                            <td class="body3 pale_outcome_color">(0.10)</td>
                          </tr>
                                                                    
                                          </tbody></table>

                                        <table class="data_table" style="padding:2px; margin-top:1ex; border:none;" width="100%" cellspacing="0" cellpadding="2" border="0">
                      <tbody><tr style="vertical-align:top;">
                        <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[1]</th>
                        <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional details about the analysis, such as null hypothesis and power calculation:</td>
                                              </tr>
                      <tr>
                        <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                        <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                      Analysis at Week 
12. The change from baseline in monthly mean sum of dysmenorrhea and 
non-menstrual pelvic pain scores was analyzed using a mixed-effects 
repeated measures analysis of covariance model. The model included fixed
 effects for treatment, time, the treatment-by-time interaction, a 
random effect for participant, the baseline-by-time interaction and the 
baseline value as a covariate.
                                                  </td>
                      </tr>

                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left;" nowrap="nowrap">[2]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Details of power calculation, definition of non-inferiority margin, and other key parameters:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[3]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant method information, such as adjustments or degrees of freedom:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[4]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Additional
 information, such as whether or not the p-value is adjusted for 
multiple comparisons and the a priori threshold for statistical 
significance:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                      
                                              <tr style="vertical-align:top;">
                          <th class="header3 note_outcome_color" style="padding:2px; margin:0px; border:none; text-align:left; white-space:nowrap;">[5]</th>
                          <td class="body3" style="padding:2px 2px 2px 1em; margin:0ex; border:none;">Other relevant estimation information:</td>
                                                  </tr>
                        <tr>
                          <td style="padding:2px; margin-top:1ex; border:none;">&nbsp;</td>
                          <td class="body3" style="padding:2px 2px 2px 2em; margin:0ex; border:none;">
                                                          No text entered.
                                                      </td>
                        </tr>
                                                                   
                    </tbody></table>
                  </div>
                                            <br>
              <br>
                              </div>
              <a name="outcome6" id="outcome6"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">6.&nbsp; Secondary: &nbsp; </td>
            <td>Change From Baseline in the Percentage of Days of Any Analgesic Use &nbsp; [ Time Frame: Baseline, Weeks 4, 8 and 12 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Change From Baseline in the Percentage of Days of Any Analgesic Use</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">The
 daily use of endometriosis analgesics was reported by participants 
daily using the e-Diary. Participants reported whether the medication 
was over-the-counter (OTC) or prescription, and, if prescription, 
whether the medication was a narcotic.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">The percentage of days 
of any analgesic use is defined as the number of days in the 4 weeks 
prior to each study visit that the participant reported the use of an 
analgesic, divided by the number of study days in the interval that the 
participant provided an e-Diary report regarding the use of 
endometriosis analgesics (including a response of “none”).</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline, Weeks 4, 8 and 12 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 1 evaluable 
e-Diary report following randomization (intent-to-treat population). The
 analysis includes participants with non-missing data at each time 
point.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and placebo intramuscular injection once a month for 12 weeks. At 
the end of 12 weeks participants were re-randomized to receive one of 
the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 150 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 150 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 250 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 250 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 250 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Leuprorelin</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and leuprorelin acetate 1-month depot 3.75 mg intramuscular 
injection once a month for 12 weeks. At the end of 12 weeks participants
 were re-randomized to receive one of the two doses of elagolix (150 mg 
or 250 mg) for 12 weeks.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 250 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Leuprorelin&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;43&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;43&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;44&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;44&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Change From Baseline in the Percentage of Days of Any Analgesic Use&nbsp;                        <br><span class="body3">[Units:&nbsp;Percentage&nbsp;of&nbsp;days]<br>Least Squares Mean (Standard Error)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 4&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 4&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-5.2&nbsp;&nbsp;(2.0)&nbsp;   
                                                                        
                           </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-1.1&nbsp;&nbsp;(2.0)&nbsp;   
                                                                        
                           </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-8.4&nbsp;&nbsp;(2.0)&nbsp;   
                                                                        
                           </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-8.7&nbsp;&nbsp;(2.0)&nbsp;   
                                                                        
                           </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 8&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 8&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-6.2&nbsp;&nbsp;(2.0)&nbsp;   
                                                                        
                           </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-3.4&nbsp;&nbsp;(2.0)&nbsp;   
                                                                        
                           </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-9.1&nbsp;&nbsp;(2.0)&nbsp;   
                                                                        
                           </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-10.2&nbsp;&nbsp;(2.0)&nbsp;  
                                                                        
                            </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 12&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;42&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;42&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 12&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-6.2&nbsp;&nbsp;(2.0)&nbsp;   
                                                                        
                           </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-4.4&nbsp;&nbsp;(2.0)&nbsp;   
                                                                        
                           </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-8.3&nbsp;&nbsp;(2.0)&nbsp;   
                                                                        
                           </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-10.5&nbsp;&nbsp;(2.0)&nbsp;  
                                                                        
                            </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                              <span class="header3">No statistical analysis provided for Change From Baseline in the Percentage of Days of Any Analgesic Use</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome7" id="outcome7"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">7.&nbsp; Secondary: &nbsp; </td>
            <td>Change From Baseline in the Percentage of Days of Prescription Analgesic Use &nbsp; [ Time Frame: Baseline, Weeks 4, 8 and 12 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Change From Baseline in the Percentage of Days of Prescription Analgesic Use</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">The
 daily use of endometriosis analgesics was reported by participants 
daily using the e-Diary. Participants reported whether the medication 
was over-the-counter (OTC) or prescription, and, if prescription, 
whether the medication was a narcotic.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">The percentage of days 
of prescription analgesic use is defined as the number of days in the 4 
weeks prior to each study visit that the participant reported the use of
 a prescription analgesic, divided by the number of study days in the 
interval that the participant provided an e-Diary report regarding the 
use of endometriosis analgesics (including a response of “none”).</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline, Weeks 4, 8 and 12 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 1 evaluable 
e-Diary report following randomization (intent-to-treat population). The
 analysis includes participants with non-missing data at each time 
point.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and placebo intramuscular injection once a month for 12 weeks. At 
the end of 12 weeks participants were re-randomized to receive one of 
the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 150 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 150 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 250 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 250 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 250 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Leuprorelin</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and leuprorelin acetate 1-month depot 3.75 mg intramuscular 
injection once a month for 12 weeks. At the end of 12 weeks participants
 were re-randomized to receive one of the two doses of elagolix (150 mg 
or 250 mg) for 12 weeks.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 250 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Leuprorelin&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;43&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;43&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;44&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;44&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Change From Baseline in the Percentage of Days 
of Prescription Analgesic Use&nbsp;                        <br><span class="body3">[Units:&nbsp;Percentage&nbsp;of&nbsp;days]<br>Least Squares Mean (Standard Error)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 4&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 4&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.3&nbsp;&nbsp;(1.8)&nbsp;   
                                                                        
                           </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;3.4&nbsp;&nbsp;(1.8)&nbsp;    
                                                                        
                          </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-1.2&nbsp;&nbsp;(1.7)&nbsp;   
                                                                        
                           </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-2.5&nbsp;&nbsp;(1.7)&nbsp;   
                                                                        
                           </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 8&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 8&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-1.3&nbsp;&nbsp;(1.6)&nbsp;   
                                                                        
                           </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;1.3&nbsp;&nbsp;(1.6)&nbsp;    
                                                                        
                          </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-2.8&nbsp;&nbsp;(1.6)&nbsp;   
                                                                        
                           </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-2.6&nbsp;&nbsp;(1.6)&nbsp;   
                                                                        
                           </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 12&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;42&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;42&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 12&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-1.8&nbsp;&nbsp;(1.4)&nbsp;   
                                                                        
                           </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;0.7&nbsp;&nbsp;(1.4)&nbsp;    
                                                                        
                          </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-1.9&nbsp;&nbsp;(1.4)&nbsp;   
                                                                        
                           </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-2.8&nbsp;&nbsp;(1.3)&nbsp;   
                                                                        
                           </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                              <span class="header3">No statistical analysis provided for Change From Baseline in the Percentage of Days of Prescription Analgesic Use</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome8" id="outcome8"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">8.&nbsp; Secondary: &nbsp; </td>
            <td>Change From Baseline in the Percentage of Days of Narcotic Analgesic Use &nbsp; [ Time Frame: Baseline, Weeks 4, 8 and 12 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Change From Baseline in the Percentage of Days of Narcotic Analgesic Use</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">The
 daily use of endometriosis analgesics was reported by participants 
daily using the e-Diary. Participants reported whether the medication 
was over-the-counter (OTC) or prescription, and, if prescription, 
whether the medication was a narcotic.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">The percentage of days 
of narcotic analgesic use is defined as the number of days in the 4 
weeks prior to each study visit that the participant reported the use of
 a narcotic analgesic, divided by the number of study days in the 
interval that the participant provided an e-Diary report regarding the 
use of endometriosis analgesics (including a response of “none”).</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline, Weeks 4, 8 and 12 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 1 evaluable 
e-Diary report following randomization (intent-to-treat population). The
 analysis includes participants with non-missing data at each time 
point.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and placebo intramuscular injection once a month for 12 weeks. At 
the end of 12 weeks participants were re-randomized to receive one of 
the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 150 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 150 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 250 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 250 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 250 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Leuprorelin</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and leuprorelin acetate 1-month depot 3.75 mg intramuscular 
injection once a month for 12 weeks. At the end of 12 weeks participants
 were re-randomized to receive one of the two doses of elagolix (150 mg 
or 250 mg) for 12 weeks.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 250 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Leuprorelin&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;43&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;43&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;44&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;44&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Change From Baseline in the Percentage of Days of Narcotic Analgesic Use&nbsp;                        <br><span class="body3">[Units:&nbsp;Percentage&nbsp;of&nbsp;days]<br>Least Squares Mean (Standard Error)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 4&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 4&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;0.0&nbsp;&nbsp;(0.1)&nbsp;    
                                                                        
                          </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.1&nbsp;&nbsp;(0.1)&nbsp;   
                                                                        
                           </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;0.0&nbsp;&nbsp;(0.1)&nbsp;    
                                                                        
                          </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.1&nbsp;&nbsp;(0.1)&nbsp;   
                                                                        
                           </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 8&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 8&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.1&nbsp;&nbsp;(0.1)&nbsp;   
                                                                        
                           </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.1&nbsp;&nbsp;(0.1)&nbsp;   
                                                                        
                           </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.1&nbsp;&nbsp;(0.1)&nbsp;   
                                                                        
                           </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.1&nbsp;&nbsp;(0.1)&nbsp;   
                                                                        
                           </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 12&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;42&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;42&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 12&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;0.0&nbsp;&nbsp;(0.1)&nbsp;    
                                                                        
                          </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;0.1&nbsp;&nbsp;(0.1)&nbsp;    
                                                                        
                          </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;0.1&nbsp;&nbsp;(0.1)&nbsp;    
                                                                        
                          </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;0.3&nbsp;&nbsp;(0.1)&nbsp;    
                                                                        
                          </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                              <span class="header3">No statistical analysis provided for Change From Baseline in the Percentage of Days of Narcotic Analgesic Use</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome9" id="outcome9"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">9.&nbsp; Secondary: &nbsp; </td>
            <td>Change From Baseline in Dyspareunia Component of the 
Composite Pelvic Signs and Symptoms Score (CPSSS) &nbsp; [ Time Frame: 
Baseline and Weeks 4, 8, and 12 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Change From Baseline in Dyspareunia Component of the Composite Pelvic Signs and Symptoms Score (CPSSS)</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">The
 CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, 
non-menstrual pelvic pain, pelvic tenderness, and pelvic induration.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">To assess dyspareunia 
(painful intercourse) participants were asked to select the best 
description of pain during sexual intercourse over the past 28 days 
using the following response categories:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">0 = Absent; No discomfort during sexual intercourse.</li>
    <li style="margin-top:0.7ex;">1 = Mild; I can tolerate the discomfort during sexual intercourse.</li>
    <li style="margin-top:0.7ex;">2 = Moderate; Intercourse is sometime interrupted due to pain.</li>
    <li style="margin-top:0.7ex;">3 = Severe; I prefer to avoid intercourse because of pain.</li>
    <li style="margin-top:0.7ex;">Not applicable. I am not sexually active for reasons other than my endometriosis symptoms.</li>
  </ul>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and Weeks 4, 8, and 12 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 1 evaluable 
e-Diary report following randomization (intent-to-treat population). The
 analysis includes participants with non-missing data at baseline and at
 each time point.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and placebo intramuscular injection once a month for 12 weeks. At 
the end of 12 weeks participants were re-randomized to receive one of 
the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 150 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 150 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 250 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 250 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 250 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Leuprorelin</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and leuprorelin acetate 1-month depot 3.75 mg intramuscular 
injection once a month for 12 weeks. At the end of 12 weeks participants
 were re-randomized to receive one of the two doses of elagolix (150 mg 
or 250 mg) for 12 weeks.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 250 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Leuprorelin&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;40&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;38&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;40&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;41&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Change From Baseline in Dyspareunia Component of
 the Composite Pelvic Signs and Symptoms Score (CPSSS)&nbsp;            
            <br><span class="body3">[Units:&nbsp;Units&nbsp;on&nbsp;a&nbsp;scale]<br>Least Squares Mean (Standard Error)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 4&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;38&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;36&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;39&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;39&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 4&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.33&nbsp;&nbsp;(0.11)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.46&nbsp;&nbsp;(0.11)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.49&nbsp;&nbsp;(0.11)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.55&nbsp;&nbsp;(0.11)&nbsp; 
                                                                        
                             </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 8&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;37&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;36&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;39&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;38&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 8&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.72&nbsp;&nbsp;(0.11)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.68&nbsp;&nbsp;(0.11)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.77&nbsp;&nbsp;(0.11)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.76&nbsp;&nbsp;(0.11)&nbsp; 
                                                                        
                             </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 12&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;37&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;33&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;40&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;37&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 12&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.60&nbsp;&nbsp;(0.11)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.84&nbsp;&nbsp;(0.12)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-0.89&nbsp;&nbsp;(0.11)&nbsp; 
                                                                        
                             </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-1.04&nbsp;&nbsp;(0.11)&nbsp; 
                                                                        
                             </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                              <span class="header3">No statistical 
analysis provided for Change From Baseline in Dyspareunia Component of 
the Composite Pelvic Signs and Symptoms Score (CPSSS)</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome10" id="outcome10"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">10.&nbsp; Secondary: &nbsp; </td>
            <td>Change From Baseline in Dysmenorrhea Component of the CPSSS &nbsp; [ Time Frame: Baseline and Week 12 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Change From Baseline in Dysmenorrhea Component of the CPSSS</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">The
 CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, 
non-menstrual pelvic pain, pelvic tenderness, and pelvic induration.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">To assess dysmenorrhea 
(pain during menstruation), participants were asked to select the best 
description of painful menstruation over the past 28 days using the 
following response categories:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">0 = Absent; Amenorrhea (no bleeding) or no discomfort.</li>
    <li style="margin-top:0.7ex;">1 = Mild; Some loss of work efficiency; occasional use of analgesics.</li>
    <li style="margin-top:0.7ex;">2 = Moderate; In bed part of one day, occasional loss of work; regular use of analgesics.</li>
    <li style="margin-top:0.7ex;">3 = Severe; In bed ≥ 1 day, incapacitation; requirement for strong analgesics.</li>
  </ul>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and Week 12 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 1 evaluable 
e-Diary report following randomization (intent-to-treat population). 
Data collection for this endpoint was added via a protocol amendment; 
therefore, the analysis only includes the subset of participants 
affected by the protocol amendment.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and placebo intramuscular injection once a month for 12 weeks. At 
the end of 12 weeks participants were re-randomized to receive one of 
the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 150 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 150 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 250 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 250 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 250 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Leuprorelin</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and leuprorelin acetate 1-month depot 3.75 mg intramuscular 
injection once a month for 12 weeks. At the end of 12 weeks participants
 were re-randomized to receive one of the two doses of elagolix (150 mg 
or 250 mg) for 12 weeks.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 250 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Leuprorelin&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;20&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;19&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;23&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;24&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Change From Baseline in Dysmenorrhea Component of the CPSSS&nbsp;                        <br><span class="body3">[Units:&nbsp;Units&nbsp;on&nbsp;a&nbsp;scale]<br>Least Squares Mean (Standard Error)</span>                       </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                        
                  &nbsp;-1.03&nbsp;&nbsp;(0.17)&nbsp;                   
                                                                 </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                        
                  &nbsp;-1.29&nbsp;&nbsp;(0.17)&nbsp;                   
                                                                 </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                        
                  &nbsp;-1.47&nbsp;&nbsp;(0.16)&nbsp;                   
                                                                 </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                        
                  &nbsp;-1.75&nbsp;&nbsp;(0.15)&nbsp;                   
                                                                 </td>
                                                                  </tr>
                    
                                                </tbody></table>
            
                            <br>


                              <span class="header3">No statistical analysis provided for Change From Baseline in Dysmenorrhea Component of the CPSSS</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome11" id="outcome11"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">11.&nbsp; Secondary: &nbsp; </td>
            <td>Change From Baseline in Non-menstrual Pelvic Pain CPSSS Component &nbsp; [ Time Frame: Baseline and Week 12 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Change From Baseline in Non-menstrual Pelvic Pain CPSSS Component</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">The
 CPSSS consists of 5 components that address dysmenorrhea, dyspareunia, 
non-menstrual pelvic pain, pelvic tenderness, and pelvic induration.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">To assess non-menstrual 
pelvic pain, participants were asked to select the best description of 
pelvic pain over the past 28 days using the following response 
categories:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">0 = Absent; No discomfort.</li>
    <li style="margin-top:0.7ex;">1 = Mild; Occasional pelvic discomfort that can be treated with NSAIDs.</li>
    <li style="margin-top:0.7ex;">2 = Moderate; Noticeable discomfort or pain for most of cycle requiring regular use of NSAID or weak opiate.</li>
    <li style="margin-top:0.7ex;">3 = Severe; Pain persisting during the cycle or pain requiring strong analgesics.</li>
  </ul>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and Week 12 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 1 evaluable 
e-Diary report following randomization (intent-to-treat population). 
Data collection for this endpoint was added via a protocol amendment; 
therefore, the analysis only includes the subset of participants 
affected by the protocol amendment.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and placebo intramuscular injection once a month for 12 weeks. At 
the end of 12 weeks participants were re-randomized to receive one of 
the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 150 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 150 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 250 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 250 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 250 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Leuprorelin</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and leuprorelin acetate 1-month depot 3.75 mg intramuscular 
injection once a month for 12 weeks. At the end of 12 weeks participants
 were re-randomized to receive one of the two doses of elagolix (150 mg 
or 250 mg) for 12 weeks.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 250 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Leuprorelin&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;20&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;19&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;23&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;24&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Change From Baseline in Non-menstrual Pelvic Pain CPSSS Component&nbsp;                        <br><span class="body3">[Units:&nbsp;Units&nbsp;on&nbsp;a&nbsp;scale]<br>Least Squares Mean (Standard Error)</span>                       </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                        
                  &nbsp;-0.60&nbsp;&nbsp;(0.12)&nbsp;                   
                                                                 </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                        
                  &nbsp;-0.58&nbsp;&nbsp;(0.12)&nbsp;                   
                                                                 </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                        
                  &nbsp;-0.48&nbsp;&nbsp;(0.11)&nbsp;                   
                                                                 </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                        
                  &nbsp;-0.79&nbsp;&nbsp;(0.11)&nbsp;                   
                                                                 </td>
                                                                  </tr>
                    
                                                </tbody></table>
            
                            <br>


                              <span class="header3">No statistical analysis provided for Change From Baseline in Non-menstrual Pelvic Pain CPSSS Component</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome12" id="outcome12"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">12.&nbsp; Secondary: &nbsp; </td>
            <td>Patient Global Impression of Change at Weeks 4, 8 and 12 &nbsp; [ Time Frame: Weeks 4, 8 and 12 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Patient Global Impression of Change at Weeks 4, 8 and 12</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">The
 Patient Global Impression of Change (PGIC) is a questionnaire-based 
assessment of the change in endometriosis pain since the initiation of 
study drug. The participant was asked to select from one of seven 
response categories:</p>
  <ol style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">Very Much Improved</li>
    <li style="margin-top:0.7ex;">Much Improved</li>
    <li style="margin-top:0.7ex;">Minimally Improved</li>
    <li style="margin-top:0.7ex;">Not Changed</li>
    <li style="margin-top:0.7ex;">Minimally Worse</li>
    <li style="margin-top:0.7ex;">Much Worse</li>
    <li style="margin-top:0.7ex;">Very Much Worse</li>
  </ol>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Weeks 4, 8 and 12 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 1 evaluable 
e-Diary report following randomization (intent-to-treat population). The
 analysis includes participants with non-missing data at each time 
point.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and placebo intramuscular injection once a month for 12 weeks. At 
the end of 12 weeks participants were re-randomized to receive one of 
the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 150 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 150 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 250 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 250 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 250 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Leuprorelin</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and leuprorelin acetate 1-month depot 3.75 mg intramuscular 
injection once a month for 12 weeks. At the end of 12 weeks participants
 were re-randomized to receive one of the two doses of elagolix (150 mg 
or 250 mg) for 12 weeks.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 250 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Leuprorelin&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;43&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;43&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;44&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;44&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Patient Global Impression of Change at Weeks 4, 8 and 12&nbsp;                        <br><span class="body3">[Units:&nbsp;Units&nbsp;on&nbsp;a&nbsp;scale]<br>Mean (Standard Error)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 4&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 4&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;3.4&nbsp;&nbsp;(0.1)&nbsp;    
                                                                        
                          </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;3.0&nbsp;&nbsp;(0.1)&nbsp;    
                                                                        
                          </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;2.9&nbsp;&nbsp;(0.2)&nbsp;    
                                                                        
                          </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;3.3&nbsp;&nbsp;(0.1)&nbsp;    
                                                                        
                          </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 8&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 8&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;2.8&nbsp;&nbsp;(0.1)&nbsp;    
                                                                        
                          </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;2.5&nbsp;&nbsp;(0.2)&nbsp;    
                                                                        
                          </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;2.2&nbsp;&nbsp;(0.1)&nbsp;    
                                                                        
                          </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;2.3&nbsp;&nbsp;(0.1)&nbsp;    
                                                                        
                          </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 12&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;42&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 12&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;2.6&nbsp;&nbsp;(0.2)&nbsp;    
                                                                        
                          </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;2.4&nbsp;&nbsp;(0.1)&nbsp;    
                                                                        
                          </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;2.2&nbsp;&nbsp;(0.2)&nbsp;    
                                                                        
                          </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;2.1&nbsp;&nbsp;(0.1)&nbsp;    
                                                                        
                          </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                              <span class="header3">No statistical analysis provided for Patient Global Impression of Change at Weeks 4, 8 and 12</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome13" id="outcome13"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">13.&nbsp; Secondary: &nbsp; </td>
            <td>Percentage of Participants With a PGIC Response of 
Minimally Improved, Much Improved, or Very Much Improved &nbsp; [ Time 
Frame: Weeks 4, 8 and 12 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Percentage of Participants With a PGIC Response of Minimally Improved, Much Improved, or Very Much Improved</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">The
 PGIC is a questionnaire-based assessment of the change in endometriosis
 pain since the initiation of study drug. The participant was asked to 
select from one of seven response categories:</p>
  <ol style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">Very Much Improved</li>
    <li style="margin-top:0.7ex;">Much Improved</li>
    <li style="margin-top:0.7ex;">Minimally Improved</li>
    <li style="margin-top:0.7ex;">Not Changed</li>
    <li style="margin-top:0.7ex;">Minimally Worse</li>
    <li style="margin-top:0.7ex;">Much Worse</li>
    <li style="margin-top:0.7ex;">Very Much Worse</li>
  </ol>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Weeks 4, 8 and 12 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 1 evaluable 
e-Diary report following randomization (intent-to-treat population). The
 analysis includes participants with non-missing data at each time 
point.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and placebo intramuscular injection once a month for 12 weeks. At 
the end of 12 weeks participants were re-randomized to receive one of 
the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 150 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 150 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 250 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 250 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 250 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Leuprorelin</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and leuprorelin acetate 1-month depot 3.75 mg intramuscular 
injection once a month for 12 weeks. At the end of 12 weeks participants
 were re-randomized to receive one of the two doses of elagolix (150 mg 
or 250 mg) for 12 weeks.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 250 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Leuprorelin&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;43&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;43&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;44&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;44&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Percentage of Participants With a PGIC Response 
of Minimally Improved, Much Improved, or Very Much Improved&nbsp;       
                 <br><span class="body3">[Units:&nbsp;Percentage&nbsp;of&nbsp;participants]<br>Number (95% Confidence Interval)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 4&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 4&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;56.1&nbsp;<br>
                                      &nbsp;(40.9&nbsp;to&nbsp;71.3)&nbsp;
                                                                                                      </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;74.4&nbsp;<br>
                                      &nbsp;(61.4&nbsp;to&nbsp;87.5)&nbsp;
                                                                                                      </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;65.1&nbsp;<br>
                                      &nbsp;(50.9&nbsp;to&nbsp;79.4)&nbsp;
                                                                                                      </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;50.0&nbsp;<br>
                                      &nbsp;(35.2&nbsp;to&nbsp;64.8)&nbsp;
                                                                                                      </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 8&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 8&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;75.6&nbsp;<br>
                                      &nbsp;(62.5&nbsp;to&nbsp;88.8)&nbsp;
                                                                                                      </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;81.4&nbsp;<br>
                                      &nbsp;(69.8&nbsp;to&nbsp;93.0)&nbsp;
                                                                                                      </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;90.7&nbsp;<br>
                                      &nbsp;(82.0&nbsp;to&nbsp;99.4)&nbsp;
                                                                                                      </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;88.6&nbsp;<br>
                                      &nbsp;(79.3&nbsp;to&nbsp;98.0)&nbsp;
                                                                                                      </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 12&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;42&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 12&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;80.5&nbsp;<br>
                                      &nbsp;(68.4&nbsp;to&nbsp;92.6)&nbsp;
                                                                                                      </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;88.1&nbsp;<br>
                                      &nbsp;(78.3&nbsp;to&nbsp;97.9)&nbsp;
                                                                                                      </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;88.4&nbsp;<br>
                                      &nbsp;(78.8&nbsp;to&nbsp;98.0)&nbsp;
                                                                                                      </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;93.2&nbsp;<br>
                                      &nbsp;(85.7&nbsp;to&nbsp;100.0)&nbsp;
                                                                                                      </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                              <span class="header3">No statistical 
analysis provided for Percentage of Participants With a PGIC Response of
 Minimally Improved, Much Improved, or Very Much Improved</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome14" id="outcome14"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">14.&nbsp; Secondary: &nbsp; </td>
            <td>Percentage of Participants With a PGIC Response of Much Improved or Very Much Improved &nbsp; [ Time Frame: Weeks 4, 8 and 12 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Percentage of Participants With a PGIC Response of Much Improved or Very Much Improved</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">The
 PGIC is a questionnaire-based assessment of the change in endometriosis
 pain since the initiation of study drug. The participant was asked to 
select from one of seven response categories:</p>
  <ol style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">Very Much Improved</li>
    <li style="margin-top:0.7ex;">Much Improved</li>
    <li style="margin-top:0.7ex;">Minimally Improved</li>
    <li style="margin-top:0.7ex;">Not Changed</li>
    <li style="margin-top:0.7ex;">Minimally Worse</li>
    <li style="margin-top:0.7ex;">Much Worse</li>
    <li style="margin-top:0.7ex;">Very Much Worse</li>
  </ol>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Weeks 4, 8 and 12 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 1 evaluable 
e-Diary report following randomization (intent-to-treat population). The
 analysis includes participants with non-missing data at each time 
point.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and placebo intramuscular injection once a month for 12 weeks. At 
the end of 12 weeks participants were re-randomized to receive one of 
the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 150 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 150 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 250 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 250 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 250 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Leuprorelin</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and leuprorelin acetate 1-month depot 3.75 mg intramuscular 
injection once a month for 12 weeks. At the end of 12 weeks participants
 were re-randomized to receive one of the two doses of elagolix (150 mg 
or 250 mg) for 12 weeks.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 250 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Leuprorelin&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;43&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;43&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;44&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;44&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Percentage of Participants With a PGIC Response 
of Much Improved or Very Much Improved&nbsp;                        <br><span class="body3">[Units:&nbsp;Percentage&nbsp;of&nbsp;participants]<br>Number (95% Confidence Interval)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 4&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 4&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;7.3&nbsp;<br>
                                      &nbsp;(0.0&nbsp;to&nbsp;15.3)&nbsp;
                                                                                                      </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;25.6&nbsp;<br>
                                      &nbsp;(12.5&nbsp;to&nbsp;38.6)&nbsp;
                                                                                                      </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;32.6&nbsp;<br>
                                      &nbsp;(18.6&nbsp;to&nbsp;46.6)&nbsp;
                                                                                                      </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;27.3&nbsp;<br>
                                      &nbsp;(14.1&nbsp;to&nbsp;40.4)&nbsp;
                                                                                                      </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 8&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 8&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;36.6&nbsp;<br>
                                      &nbsp;(21.8&nbsp;to&nbsp;51.3)&nbsp;
                                                                                                      </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;53.5&nbsp;<br>
                                      &nbsp;(38.6&nbsp;to&nbsp;68.4)&nbsp;
                                                                                                      </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;72.1&nbsp;<br>
                                      &nbsp;(58.7&nbsp;to&nbsp;85.5)&nbsp;
                                                                                                      </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;54.5&nbsp;<br>
                                      &nbsp;(39.8&nbsp;to&nbsp;69.3)&nbsp;
                                                                                                      </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 12&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;42&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 12&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;53.7&nbsp;<br>
                                      &nbsp;(38.4&nbsp;to&nbsp;68.9)&nbsp;
                                                                                                      </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;54.8&nbsp;<br>
                                      &nbsp;(39.7&nbsp;to&nbsp;69.8)&nbsp;
                                                                                                      </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;67.4&nbsp;<br>
                                      &nbsp;(53.4&nbsp;to&nbsp;81.4)&nbsp;
                                                                                                      </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;70.5&nbsp;<br>
                                      &nbsp;(57.0&nbsp;to&nbsp;83.9)&nbsp;
                                                                                                      </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                              <span class="header3">No statistical analysis provided for Percentage of Participants With a PGIC Response of Much Improved or Very Much Improved</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome15" id="outcome15"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">15.&nbsp; Secondary: &nbsp; </td>
            <td>Change From Baseline in Endometriosis Health Profile-5 (EHP-5) at Week 12 &nbsp; [ Time Frame: Baseline and week 12 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Change From Baseline in Endometriosis Health Profile-5 (EHP-5) at Week 12</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">The
 EHP-5 is an instrument to measure health-related quality of life in 
women with endometriosis. The EHP-5 consists of two parts:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">A core questionnaire consisting of 
five questions that measure the areas of pain, control and 
powerlessness, emotional well-being, social support, and self-image with
 five response categories for each item (Never, Rarely, Sometimes, 
Often, Always)</li>
    <li style="margin-top:0.7ex;">A supplemental questionnaire 
consisting of six additional questions which assess the areas of work, 
relationship with children, sexual intercourse, feelings about the 
medical profession, treatment, and infertility with the same five 
response categories plus an additional response category of Not Relevant
 which was not scored.</li>
  </ul>
  <p style="margin-top:0ex; margin-bottom:1ex;">The scores associated 
with each possible outcome category are as follows: never (0), rarely 
(25), sometimes (50), often (75), and always (100). A negative change 
from baseline score indicates improvement in quality of life.</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and week 12 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          All randomized participants 
who received at least 1 dose of study drug and had at least 1 evaluable 
e-Diary report following randomization (intent-to-treat population). The
 analysis includes participants with non-missing data for each dimension
 at baseline and week 12.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and placebo intramuscular injection once a month for 12 weeks. At 
the end of 12 weeks participants were re-randomized to receive one of 
the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 150 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 150 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 250 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 250 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 250 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Leuprorelin</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and leuprorelin acetate 1-month depot 3.75 mg intramuscular 
injection once a month for 12 weeks. At the end of 12 weeks participants
 were re-randomized to receive one of the two doses of elagolix (150 mg 
or 250 mg) for 12 weeks.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 250 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Leuprorelin&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;43&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;43&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;44&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;44&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Change From Baseline in Endometriosis Health Profile-5 (EHP-5) at Week 12&nbsp;                        <br><span class="body3">[Units:&nbsp;Units&nbsp;on&nbsp;a&nbsp;scale]<br>Mean (Standard Error)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Pain&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;42&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Pain&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-14.0&nbsp;&nbsp;(4.8)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-19.0&nbsp;&nbsp;(4.1)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-25.0&nbsp;&nbsp;(4.7)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-31.8&nbsp;&nbsp;(3.9)&nbsp;  
                                                                        
                            </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Control and Powerlessness&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;42&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Control and Powerlessness&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-18.3&nbsp;&nbsp;(4.4)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-17.9&nbsp;&nbsp;(3.9)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-20.9&nbsp;&nbsp;(5.1)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-23.9&nbsp;&nbsp;(4.9)&nbsp;  
                                                                        
                            </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Emotional Wellbeing&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;42&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Emotional Wellbeing&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-14.6&nbsp;&nbsp;(4.2)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-10.7&nbsp;&nbsp;(4.1)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-12.8&nbsp;&nbsp;(4.4)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-13.6&nbsp;&nbsp;(4.4)&nbsp;  
                                                                        
                            </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Social Support&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;42&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Social Support&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-22.0&nbsp;&nbsp;(4.4)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-16.1&nbsp;&nbsp;(4.4)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-18.6&nbsp;&nbsp;(5.6)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-15.3&nbsp;&nbsp;(5.1)&nbsp;  
                                                                        
                            </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Self-image&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;42&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;44&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Self-image&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-12.2&nbsp;&nbsp;(6.5)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-7.7&nbsp;&nbsp;(4.5)&nbsp;   
                                                                        
                           </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-5.8&nbsp;&nbsp;(5.0)&nbsp;   
                                                                        
                           </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-8.5&nbsp;&nbsp;(4.1)&nbsp;   
                                                                        
                           </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Work&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;39&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;36&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;36&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;35&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Work&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-23.7&nbsp;&nbsp;(3.9)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-21.5&nbsp;&nbsp;(4.5)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-29.9&nbsp;&nbsp;(5.1)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-38.6&nbsp;&nbsp;(4.3)&nbsp;  
                                                                        
                            </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Relationship with Children&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;13&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;18&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;16&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;12&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Relationship with Children&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-11.5&nbsp;&nbsp;(6.7)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-15.3&nbsp;&nbsp;(5.4)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-25.0&nbsp;&nbsp;(7.6)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-22.9&nbsp;&nbsp;(9.5)&nbsp;  
                                                                        
                            </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Sexual Intercourse&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;38&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;33&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;40&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;38&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Sexual Intercourse&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-32.2&nbsp;&nbsp;(5.7)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-21.2&nbsp;&nbsp;(6.2)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-30.6&nbsp;&nbsp;(5.3)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-28.9&nbsp;&nbsp;(5.7)&nbsp;  
                                                                        
                            </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Medical Profession&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;33&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;32&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;33&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;32&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Medical Profession&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-5.3&nbsp;&nbsp;(4.5)&nbsp;   
                                                                        
                           </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-5.5&nbsp;&nbsp;(4.0)&nbsp;   
                                                                        
                           </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-7.6&nbsp;&nbsp;(3.0)&nbsp;   
                                                                        
                           </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-6.3&nbsp;&nbsp;(4.2)&nbsp;   
                                                                        
                           </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Frustration with Treatment&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;22&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;23&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;23&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;22&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Frustration with Treatment&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-11.4&nbsp;&nbsp;(6.1)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-10.9&nbsp;&nbsp;(6.3)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-7.6&nbsp;&nbsp;(6.9)&nbsp;   
                                                                        
                           </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-12.5&nbsp;&nbsp;(6.9)&nbsp;  
                                                                        
                            </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Concerns with Infertility&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;33&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;25&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;29&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;30&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Concerns with Infertility&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-19.7&nbsp;&nbsp;(5.0)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-24.0&nbsp;&nbsp;(7.0)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-13.8&nbsp;&nbsp;(5.2)&nbsp;  
                                                                        
                            </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                        
                                    &nbsp;-13.3&nbsp;&nbsp;(4.8)&nbsp;  
                                                                        
                            </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                              <span class="header3">No statistical analysis provided for Change From Baseline in Endometriosis Health Profile-5 (EHP-5) at Week 12</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome16" id="outcome16"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">16.&nbsp; Secondary: &nbsp; </td>
            <td>Concentration of Serum Estradiol &nbsp; [ Time Frame: Baseline and Weeks 4, 8 and 12 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Concentration of Serum Estradiol</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          The concentration of serum 
estradiol (E2) was quantified using liquid chromatography with tandem 
mass spectrophotometry (LC/MS/MS). Serum estradiol concentrations below 
the limit of quantification (BLQ) were set equal to the lower limit of 
quantification (2.5 pg/mL).
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and Weeks 4, 8 and 12 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          Randomized participants who 
received at least one dose of randomized, double-blind study drug with 
at least one eDiary value following randomization, excluding 
participants who had less than 80% oral study drug dosing compliance 
during Weeks 1-12 (per protocol population). The analysis includes 
participants with non-missing data at each time point.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and placebo intramuscular injection once a month for 12 weeks. At 
the end of 12 weeks participants were re-randomized to receive one of 
the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 150 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 150 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 250 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 250 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 250 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Leuprorelin</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and leuprorelin acetate 1-month depot 3.75 mg intramuscular 
injection once a month for 12 weeks. At the end of 12 weeks participants
 were re-randomized to receive one of the two doses of elagolix (150 mg 
or 250 mg) for 12 weeks.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 250 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Leuprorelin&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;43&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;41&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;43&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;44&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Concentration of Serum Estradiol&nbsp;                        <br><span class="body3">[Units:&nbsp;pg/mL]<br>Median (Full Range)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Baseline&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Baseline&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;39.10&nbsp;<br>
                                      &nbsp;(12.0&nbsp;to&nbsp;168.0)&nbsp;
                                                                                                      </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;43.40&nbsp;<br>
                                      &nbsp;(2.5&nbsp;to&nbsp;199.0)&nbsp;
                                                                                                      </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;47.50&nbsp;<br>
                                      &nbsp;(12.4&nbsp;to&nbsp;497.0)&nbsp;
                                                                                                      </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;46.20&nbsp;<br>
                                      &nbsp;(19.6&nbsp;to&nbsp;154.0)&nbsp;
                                                                                                      </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 4&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;42&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;40&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;43&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;42&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 4&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;49.50&nbsp;<br>
                                      &nbsp;(14.6&nbsp;to&nbsp;436.0)&nbsp;
                                                                                                      </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;36.40&nbsp;<br>
                                      &nbsp;(4.5&nbsp;to&nbsp;247.0)&nbsp;
                                                                                                      </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;22.00&nbsp;<br>
                                      &nbsp;(6.2&nbsp;to&nbsp;127.0)&nbsp;
                                                                                                      </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;3.63&nbsp;<br>
                                      &nbsp;(2.5&nbsp;to&nbsp;87.5)&nbsp;
                                                                                                      </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 8&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;39&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;42&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;42&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 8&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;61.00&nbsp;<br>
                                      &nbsp;(12.7&nbsp;to&nbsp;440.0)&nbsp;
                                                                                                      </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;36.90&nbsp;<br>
                                      &nbsp;(6.8&nbsp;to&nbsp;182.0)&nbsp;
                                                                                                      </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;23.65&nbsp;<br>
                                      &nbsp;(2.5&nbsp;to&nbsp;213.0)&nbsp;
                                                                                                      </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;4.36&nbsp;<br>
                                      &nbsp;(2.5&nbsp;to&nbsp;44.9)&nbsp;
                                                                                                      </td>
                                                                                    </tr>
                                                                                        <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Week 12&nbsp;                                                  </td>
                                                                              <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                      <td class="br pale_outcome_color">&nbsp;</td>
                                                                        </tr>
                                                                        <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Participants Analyzed&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;27&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;41&nbsp;                                                          
        </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                      
&nbsp;30&nbsp;                                                          
        </td>
                                                                                    </tr>
                                                  <tr>
                            <td class="header3 br bold_outcome_color" style="padding:0px 5px 2px 4em;">
                              Week 12&nbsp;                                                          </td>
                                                                                          <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;87.90&nbsp;<br>
                                      &nbsp;(2.5&nbsp;to&nbsp;338.0)&nbsp;
                                                                                                      </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;36.70&nbsp;<br>
                                      &nbsp;(2.5&nbsp;to&nbsp;521.0)&nbsp;
                                                                                                      </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;26.20&nbsp;<br>
                                      &nbsp;(2.5&nbsp;to&nbsp;235.0)&nbsp;
                                                                                                      </td>
                                                              <td class="header3 br pale_outcome_color" style="padding:0px 5px 2px 5px;text-align:center;">
                                                                                                            &nbsp;6.38&nbsp;<br>
                                      &nbsp;(2.5&nbsp;to&nbsp;421.0)&nbsp;
                                                                                                      </td>
                                                                                    </tr>
                                                                                                                  </tbody></table>
            
                            <br>


                              <span class="header3">No statistical analysis provided for Concentration of Serum Estradiol</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome17" id="outcome17"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">17.&nbsp; Secondary: &nbsp; </td>
            <td>Percent Change From Baseline in Bone Mineral Density of the Femur at Week 12 &nbsp; [ Time Frame: Baseline and week 12 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Percent Change From Baseline in Bone Mineral Density of the Femur at Week 12</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          Bone mineral density (BMD) of 
the femur (total hip) was measured by dual-energy X-ray absorptiometry 
(DXA).
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and week 12 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          Participants who received at 
least one dose of randomized, double-blind study drug (safety analysis 
set) and with available BMD data at baseline and week 12.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and placebo intramuscular injection once a month for 12 weeks. At 
the end of 12 weeks participants were re-randomized to receive one of 
the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 150 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 150 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 250 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 250 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 250 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Leuprorelin</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and leuprorelin acetate 1-month depot 3.75 mg intramuscular 
injection once a month for 12 weeks. At the end of 12 weeks participants
 were re-randomized to receive one of the two doses of elagolix (150 mg 
or 250 mg) for 12 weeks.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 250 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Leuprorelin&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;40&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;41&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;42&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;43&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Percent Change From Baseline in Bone Mineral 
Density of the Femur at Week 12&nbsp;                        <br><span class="body3">[Units:&nbsp;Percent&nbsp;change]<br>Mean (Standard Deviation)</span>                       </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                        
                  &nbsp;-0.90&nbsp;&nbsp;(1.316)&nbsp;                  
                                                                  </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                        
                  &nbsp;-0.342&nbsp;&nbsp;(1.583)&nbsp;                 
                                                                   </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                        
                  &nbsp;-0.5623&nbsp;&nbsp;(1.367)&nbsp;                
                                                                    </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                        
                  &nbsp;-1.122&nbsp;&nbsp;(1.634)&nbsp;                 
                                                                   </td>
                                                                  </tr>
                    
                                                </tbody></table>
            
                            <br>


                              <span class="header3">No statistical analysis provided for Percent Change From Baseline in Bone Mineral Density of the Femur at Week 12</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome18" id="outcome18"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">18.&nbsp; Secondary: &nbsp; </td>
            <td>Percent Change From Baseline in Bone Mineral Density of the Spine at Week 12 &nbsp; [ Time Frame: Baseline and week 12 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Percent Change From Baseline in Bone Mineral Density of the Spine at Week 12</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          Bone mineral density (BMD) of 
the spine was measured by dual-energy X-ray absorptiometry (DXA).
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and week 12 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          Participants who received at 
least one dose of randomized, double-blind study drug (safety analysis 
set) and with available BMD data at baseline and week 12.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and placebo intramuscular injection once a month for 12 weeks. At 
the end of 12 weeks participants were re-randomized to receive one of 
the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 150 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 150 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 250 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 250 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 250 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Leuprorelin</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and leuprorelin acetate 1-month depot 3.75 mg intramuscular 
injection once a month for 12 weeks. At the end of 12 weeks participants
 were re-randomized to receive one of the two doses of elagolix (150 mg 
or 250 mg) for 12 weeks.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 250 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Leuprorelin&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;40&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;41&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;42&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;44&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Percent Change From Baseline in Bone Mineral 
Density of the Spine at Week 12&nbsp;                        <br><span class="body3">[Units:&nbsp;Percent&nbsp;change]<br>Mean (Standard Deviation)</span>                       </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                        
                  &nbsp;0.106&nbsp;&nbsp;(1.893)&nbsp;                  
                                                                  </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                        
                  &nbsp;-1.053&nbsp;&nbsp;(1.985)&nbsp;                 
                                                                   </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                        
                  &nbsp;-0.799&nbsp;&nbsp;(2.352)&nbsp;                 
                                                                   </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                        
                  &nbsp;-1.633&nbsp;&nbsp;(2.113)&nbsp;                 
                                                                   </td>
                                                                  </tr>
                    
                                                </tbody></table>
            
                            <br>


                              <span class="header3">No statistical analysis provided for Percent Change From Baseline in Bone Mineral Density of the Spine at Week 12</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome19" id="outcome19"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">19.&nbsp; Secondary: &nbsp; </td>
            <td>Percent Change From Baseline in Bone Mineral Density of the Femur at Week 24 &nbsp; [ Time Frame: Baseline and Week 24 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Percent Change From Baseline in Bone Mineral Density of the Femur at Week 24</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          Bone mineral density (BMD) of 
the femur (total hip) was measured by dual-energy X-ray absorptiometry 
(DXA).
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and Week 24 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          Participants who received at 
least one dose of randomized, double-blind study drug (safety analysis 
set) and with available BMD data at baseline and week 24.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 150 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 150 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 250 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 250 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 250 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo / Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants initially randomized to placebo 
were re-randomized at week 12 to receive elagolix 150 mg for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo / Elagolix 250 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants initially randomized to placebo 
were re-randomized at week 12 to receive elagolix 250 mg for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Leuprorelin / Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants initially randomized to 
leuprorelin acetate were re-randomized at week 12 to receive elagolix 
150 mg for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Leuprorelin / Elagolix 250 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants initially randomized to 
leuprorelin acetate were re-randomized at week 12 to receive elagolix 
250 mg for 12 weeks.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 250 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo / Elagolix 150 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo / Elagolix 250 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Leuprorelin / Elagolix 150 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Leuprorelin / Elagolix 250 mg&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;36&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;38&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;17&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;20&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;18&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;21&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Percent Change From Baseline in Bone Mineral 
Density of the Femur at Week 24&nbsp;                        <br><span class="body3">[Units:&nbsp;Percent&nbsp;change]<br>Mean (Standard Deviation)</span>                       </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                        
                  &nbsp;-0.549&nbsp;&nbsp;(1.827)&nbsp;                 
                                                                   </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                        
                  &nbsp;-0.699&nbsp;&nbsp;(1.574)&nbsp;                 
                                                                   </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                        
                  &nbsp;-0.126&nbsp;&nbsp;(1.732)&nbsp;                 
                                                                   </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                        
                  &nbsp;-0.573&nbsp;&nbsp;(1.328)&nbsp;                 
                                                                   </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                        
                  &nbsp;-1.784&nbsp;&nbsp;(1.571)&nbsp;                 
                                                                   </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                        
                  &nbsp;-1.783&nbsp;&nbsp;(2.096)&nbsp;                 
                                                                   </td>
                                                                  </tr>
                    
                                                </tbody></table>
            
                            <br>


                              <span class="header3">No statistical analysis provided for Percent Change From Baseline in Bone Mineral Density of the Femur at Week 24</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome20" id="outcome20"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">20.&nbsp; Secondary: &nbsp; </td>
            <td>Percent Change From Baseline in Bone Mineral Density of the Spine at Week 24 &nbsp; [ Time Frame: Baseline and Week 24 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Percent Change From Baseline in Bone Mineral Density of the Spine at Week 24</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          Bone mineral density (BMD) of 
the spine was measured by dual-energy X-ray absorptiometry (DXA).
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and Week 24 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          Participants who received at 
least one dose of randomized, double-blind study drug (safety analysis 
set) and with available BMD data at baseline and week 24.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 150 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 150 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 250 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 250 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 250 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo / Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants initially randomized to placebo 
were re-randomized at week 12 to receive elagolix 150 mg for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo / Elagolix 250 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants initially randomized to placebo 
were re-randomized at week 12 to receive elagolix 250 mg for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Leuprorelin / Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants initially randomized to 
leuprorelin acetate were re-randomized at week 12 to receive elagolix 
150 mg for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Leuprorelin / Elagolix 250 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants initially randomized to 
leuprorelin acetate were re-randomized at week 12 to receive elagolix 
250 mg for 12 weeks.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 250 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo / Elagolix 150 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo / Elagolix 250 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Leuprorelin / Elagolix 150 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Leuprorelin / Elagolix 250 mg&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;35&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;39&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;17&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;20&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;18&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;21&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Percent Change From Baseline in Bone Mineral 
Density of the Spine at Week 24&nbsp;                        <br><span class="body3">[Units:&nbsp;Percent&nbsp;change]<br>Mean (Standard Deviation)</span>                       </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                        
                  &nbsp;-1.288&nbsp;&nbsp;(2.681)&nbsp;                 
                                                                   </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                        
                  &nbsp;-1.855&nbsp;&nbsp;(2.670)&nbsp;                 
                                                                   </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                        
                  &nbsp;-0.990&nbsp;&nbsp;(2.636)&nbsp;                 
                                                                   </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                        
                  &nbsp;-0.648&nbsp;&nbsp;(2.377)&nbsp;                 
                                                                   </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                        
                  &nbsp;-2.899&nbsp;&nbsp;(2.733)&nbsp;                 
                                                                   </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                        
                  &nbsp;-4.378&nbsp;&nbsp;(2.099)&nbsp;                 
                                                                   </td>
                                                                  </tr>
                    
                                                </tbody></table>
            
                            <br>


                              <span class="header3">No statistical analysis provided for Percent Change From Baseline in Bone Mineral Density of the Spine at Week 24</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome21" id="outcome21"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">21.&nbsp; Secondary: &nbsp; </td>
            <td>Change From Baseline in Serum N-telopeptide Concentration at Week 12 &nbsp; [ Time Frame: Baseline and week 12 ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Change From Baseline in Serum N-telopeptide Concentration at Week 12</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          Blood samples to determine 
N-telopeptide concentrations were analyzed by a central laboratory using
 an enzyme-linked immunosorbent assay (ELISA).
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Baseline and week 12 &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          Participants who received at 
least one dose of randomized, double-blind study drug (safety analysis 
set) and with available data at baseline and week 12.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and placebo intramuscular injection once a month for 12 weeks. At 
the end of 12 weeks participants were re-randomized to receive one of 
the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 150 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 150 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 250 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 250 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 250 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Leuprorelin</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and leuprorelin acetate 1-month depot 3.75 mg intramuscular 
injection once a month for 12 weeks. At the end of 12 weeks participants
 were re-randomized to receive one of the two doses of elagolix (150 mg 
or 250 mg) for 12 weeks.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 250 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Leuprorelin&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;39&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;43&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;41&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;40&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Change From Baseline in Serum N-telopeptide Concentration at Week 12&nbsp;                        <br><span class="body3">[Units:&nbsp;nM&nbsp;bone&nbsp;collagen&nbsp;equivalents&nbsp;(BCE)]<br>Mean (Standard Error)</span>                       </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                        
                  &nbsp;0.62&nbsp;&nbsp;(0.78)&nbsp;                    
                                                                </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                        
                  &nbsp;0.77&nbsp;&nbsp;(0.69)&nbsp;                    
                                                                </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                        
                  &nbsp;2.04&nbsp;&nbsp;(0.66)&nbsp;                    
                                                                </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                        
                  &nbsp;3.18&nbsp;&nbsp;(0.72)&nbsp;                    
                                                                </td>
                                                                  </tr>
                    
                                                </tbody></table>
            
                            <br>


                              <span class="header3">No statistical analysis provided for Change From Baseline in Serum N-telopeptide Concentration at Week 12</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome22" id="outcome22"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">22.&nbsp; Secondary: &nbsp; </td>
            <td>Average Number of Hot Flashes Per Day &nbsp; [ Time 
Frame: Screening (8 weeks prior to day 1), Treatment phase (weeks 1 to 
12 for participants in the placebo and leuprorelin treatment groups and 
weeks 1 to 24 for participants in the elagolix treatment groups) ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Average Number of Hot Flashes Per Day</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">Hot flashes, if any, were reported daily by participants during the study using the e-Diary.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">The average number of 
hot flashes per day was calculated for each participant as the total 
number of hot flashes divided by total days in the phase.</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Screening (8 
weeks prior to day 1), Treatment phase (weeks 1 to 12 for participants 
in the placebo and leuprorelin treatment groups and weeks 1 to 24 for 
participants in the elagolix treatment groups) &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          Participants who received at 
least one dose of randomized, double-blind study drug (safety analysis 
set).
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and placebo intramuscular injection once a month for 12 weeks. At 
the end of 12 weeks participants were re-randomized to receive one of 
the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 150 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 150 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 250 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 250 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 250 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Leuprorelin</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and leuprorelin acetate 1-month depot 3.75 mg intramuscular 
injection once a month for 12 weeks. At the end of 12 weeks participants
 were re-randomized to receive one of the two doses of elagolix (150 mg 
or 250 mg) for 12 weeks.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 250 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Leuprorelin&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;43&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;43&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;44&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;44&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Average Number of Hot Flashes Per Day&nbsp;                        <br><span class="body3">[Units:&nbsp;Hot&nbsp;flashes&nbsp;per&nbsp;day]<br>Median (Full Range)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Screening&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                                                                &nbsp;0.00&nbsp;<br>
                                  &nbsp;(0.0&nbsp;to&nbsp;4.8)&nbsp;
                                                                                          </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                                                                &nbsp;0.00&nbsp;<br>
                                  &nbsp;(0.0&nbsp;to&nbsp;4.6)&nbsp;
                                                                                          </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                                                                &nbsp;0.00&nbsp;<br>
                                  &nbsp;(0.0&nbsp;to&nbsp;2.6)&nbsp;
                                                                                          </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                                                                &nbsp;0.00&nbsp;<br>
                                  &nbsp;(0.0&nbsp;to&nbsp;3.7)&nbsp;
                                                                                          </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Treatment Phase&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                                                                &nbsp;0.11&nbsp;<br>
                                  &nbsp;(0.0&nbsp;to&nbsp;3.0)&nbsp;
                                                                                          </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                                                                &nbsp;0.22&nbsp;<br>
                                  &nbsp;(0.0&nbsp;to&nbsp;7.5)&nbsp;
                                                                                          </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                                                                &nbsp;1.10&nbsp;<br>
                                  &nbsp;(0.0&nbsp;to&nbsp;11.4)&nbsp;
                                                                                          </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                                                                &nbsp;1.73&nbsp;<br>
                                  &nbsp;(0.0&nbsp;to&nbsp;9.4)&nbsp;
                                                                                          </td>
                                                                        </tr>
                                                                                          </tbody></table>
            
                            <br>


                              <span class="header3">No statistical analysis provided for Average Number of Hot Flashes Per Day</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome23" id="outcome23"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">23.&nbsp; Secondary: &nbsp; </td>
            <td>Percentage of Days With Uterine Bleeding &nbsp; [ Time 
Frame: Screening (8 weeks prior to day 1), Treatment phase (weeks 1 to 
12 for participants in the placebo and leuprorelin treatment groups and 
weeks 1 to 24 for participants in the elagolix treatment groups) ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Percentage of Days With Uterine Bleeding</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          <p style="margin-top:0ex; margin-bottom:1ex;">Uterine bleeding was reported daily by participants during the study using the e-Diary.</p>
  <p style="margin-top:0ex; margin-bottom:1ex;">The percentage of days a
 participant reported any bleeding was calculated as the total number of
 days the participant reported any bleeding ( light, moderate, or heavy)
 divided by the total number of days the participant had a non-missing 
eDiary report of vaginal bleeding in the phase.</p>
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">Screening (8 
weeks prior to day 1), Treatment phase (weeks 1 to 12 for participants 
in the placebo and leuprorelin treatment groups and weeks 1 to 24 for 
participants in the elagolix treatment groups) &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          Participants who received at 
least one dose of randomized, double-blind study drug (safety analysis 
set).
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and placebo intramuscular injection once a month for 12 weeks. At 
the end of 12 weeks participants were re-randomized to receive one of 
the two doses of elagolix (150 mg or 250 mg) for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 150 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 150 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 250 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 250 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 250 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Leuprorelin</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received placebo tablets once a 
day and leuprorelin acetate 1-month depot 3.75 mg intramuscular 
injection once a month for 12 weeks. At the end of 12 weeks participants
 were re-randomized to receive one of the two doses of elagolix (150 mg 
or 250 mg) for 12 weeks.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 250 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Leuprorelin&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;43&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;43&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;44&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;44&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Percentage of Days With Uterine Bleeding&nbsp;                        <br><span class="body3">[Units:&nbsp;Percentage&nbsp;of&nbsp;days]<br>Mean (Standard Error)</span>                       </th>
                                                                        <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                  <td class="brt pale_outcome_color">&nbsp;</td>
                                                                  </tr>
                                          <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Screening&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                                        
                        &nbsp;21.10&nbsp;&nbsp;(1.78)&nbsp;             
                                                                        
     </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                                        
                        &nbsp;18.32&nbsp;&nbsp;(1.14)&nbsp;             
                                                                        
     </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                                        
                        &nbsp;22.32&nbsp;&nbsp;(1.68)&nbsp;             
                                                                        
     </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                                        
                        &nbsp;21.05&nbsp;&nbsp;(1.87)&nbsp;             
                                                                        
     </td>
                                                                        </tr>
                                                                <tr>
                        <td class="header3 br bold_outcome_color" style="padding-left:2em;">
                          Treatment Phase&nbsp;                                                  </td>
                                                                              <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                                        
                        &nbsp;21.46&nbsp;&nbsp;(1.39)&nbsp;             
                                                                        
     </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                                        
                        &nbsp;10.78&nbsp;&nbsp;(1.14)&nbsp;             
                                                                        
     </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                                        
                        &nbsp;9.54&nbsp;&nbsp;(1.35)&nbsp;              
                                                                        
    </td>
                                                      <td class="header3 br pale_outcome_color" style="text-align:center;">
                                                                        
                        &nbsp;11.04&nbsp;&nbsp;(1.30)&nbsp;             
                                                                        
     </td>
                                                                        </tr>
                                                                                          </tbody></table>
            
                            <br>


                              <span class="header3">No statistical analysis provided for Percentage of Days With Uterine Bleeding</span>
                <br>

                            <br>
              <br>
                              </div>
              <a name="outcome24" id="outcome24"></a>

        <br>
        <table class="layout_table header2" style="margin-top:0.5ex" cellspacing="0" cellpadding="0" border="0">
          <tbody><tr style="vertical-align:top;">
            <td nowrap="nowrap">24.&nbsp; Secondary: &nbsp; </td>
            <td>Number of Days to First Posttreatment Menses &nbsp; [ 
Time Frame: From last day of study drug up to 6 weeks after the last 
dose. ]</td>
          </tr>
        </tbody></table>

        <div class="body3 indent2" style="margin-top:0.5ex;">

          
            
              
              <br>
              <table class="data_table" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Type</th>
                  <td class="body3 pale_outcome_color">Secondary</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Measure&nbsp;Title</th>
                  <td class="body3 pale_outcome_color">Number of Days to First Posttreatment Menses</td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;">Measure&nbsp;Description</th>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          Defined as the number of days 
from the last dose of study drug until the start date of the first 
post-treatment menses.
                                      </td>
                </tr>
                <tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">Time&nbsp;Frame</th>
                  <td class="body3 pale_outcome_color">From last day of study drug up to 6 weeks after the last dose. &nbsp;</td>
                </tr>
              </tbody></table>
              <br>

              <span class="header3">Population Description</span>
              <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
                <tbody><tr>
                  <th class="header3 bold_outcome_color" style="text-align:left;">
                    Explanation of how the number of participants for analysis was determined.
                    Includes whether analysis was per protocol, intention to treat, or another method.
                    Also provides relevant details such as imputation technique, as appropriate.
                  </th>
                </tr>
                <tr>
                  <td class="body3 pale_outcome_color" style="vertical-align:top;">
                                          Participants who received at 
least one dose of randomized, double-blind study drug (safety analysis 
set) with non-missing post-treatment data.
                                      </td>
                </tr>
              </tbody></table>

              
              <br>
                            
  <span class="header3">Reporting Groups</span>
  <table class="data_table" style="margin-top:0.5ex" cellspacing="0" cellpadding="5" border="1">
    <tbody><tr>
      <th class="header3 bold_outcome_color">&nbsp;</th>
      <th class="header3 bold_outcome_color" style="text-align:left;">Description</th>
    </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 150 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 150 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Elagolix 250 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants received elagolix 250 mg tablets 
once a day and placebo intramuscular injection once a month for 12 
weeks. At the end of 12 weeks participants continued to receive elagolix
 250 mg for an additional 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo / Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants initially randomized to placebo 
were re-randomized at week 12 to receive elagolix 150 mg for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Placebo / Elagolix 250 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants initially randomized to placebo 
were re-randomized at week 12 to receive elagolix 250 mg for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Leuprorelin / Elagolix 150 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants initially randomized to 
leuprorelin acetate were re-randomized at week 12 to receive elagolix 
150 mg for 12 weeks.
                      </td>
        </tr>
            <tr>
          <th class="header3 bold_outcome_color" style="text-align:left;vertical-align:top;white-space:nowrap;">Leuprorelin / Elagolix 250 mg</th>
          <td class="body3 pale_outcome_color" style="vertical-align:top;">
                          Participants initially randomized to 
leuprorelin acetate were re-randomized at week 12 to receive elagolix 
250 mg for 12 weeks.
                      </td>
        </tr>
      </tbody></table>


              <br>
              <span class="header3">Measured Values</span>
              <table class="results_table" style="margin-top:0.5ex;" cellspacing="0" cellpadding="0" border="0">
                <tbody><tr>
                  <th class="brt bold_outcome_color" style="max-width:50%">&nbsp;</th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 150 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Elagolix 250 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo / Elagolix 150 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Placebo / Elagolix 250 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Leuprorelin / Elagolix 150 mg&nbsp; 
                    </th>
                                      <th class="header3 brt bold_outcome_color style=" max-width:20%;text-align:center;"="">
                      &nbsp;Leuprorelin / Elagolix 250 mg&nbsp; 
                    </th>
                                  </tr>
            
                            
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Participants Analyzed&nbsp;                                              </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;38&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;39&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;19&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;20&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;20&nbsp;                                                      </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                          &nbsp;21&nbsp;                                                      </td>
                                                                  </tr>
                    
                                              
                                      <tr>
                      <th class="header3 brt bold_outcome_color" style="text-align:left;">
                        Number of Days to First Posttreatment Menses&nbsp;                        <br><span class="body3">[Units:&nbsp;Days]<br>Median (Full Range)</span>                       </th>
                                                                        <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                                          &nbsp;22.5&nbsp;<br>
                                &nbsp;(3&nbsp;to&nbsp;56)&nbsp;
                                                                                    </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                                          &nbsp;26.0&nbsp;<br>
                                &nbsp;(10&nbsp;to&nbsp;103)&nbsp;
                                                                                    </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                                          &nbsp;26.0&nbsp;<br>
                                &nbsp;(5&nbsp;to&nbsp;42)&nbsp;
                                                                                    </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                                          &nbsp;27.0&nbsp;<br>
                                &nbsp;(2&nbsp;to&nbsp;34)&nbsp;
                                                                                    </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                                          &nbsp;29.0&nbsp;<br>
                                &nbsp;(5&nbsp;to&nbsp;62)&nbsp;
                                                                                    </td>
                                                  <td class="header3 brt pale_outcome_color" style="text-align:center;">
                                                                                          &nbsp;28.0&nbsp;<br>
                                &nbsp;(8&nbsp;to&nbsp;36)&nbsp;
                                                                                    </td>
                                                                  </tr>
                    
                                                </tbody></table>
            
                            <br>


                              <span class="header3">No statistical analysis provided for Number of Days to First Posttreatment Menses</span>
                <br>

                            <br>
              <br>
                              </div>
          </div>
</div>
  
<!-- adverse events section -->
<br>
<div class="indent1">

  <br>
  <img src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20Versus%20Placebo%20or%20Leuprorelin%20Acetate%20in%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/triangle.gif" alt=""><span class="header2">&nbsp; Serious Adverse Events</span><br>
  <a name="evnt" id="evnt"></a>
  <div class="header3 indent2">

      <div style="margin-top:1.0ex;">
      <a title="Show serious adverse events" href="https://clinicaltrials.gov/ct2/show/results/NCT00797225?sect=X301256#evnt">
        <img style="float:left" src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20Versus%20Placebo%20or%20Leuprorelin%20Acetate%20in%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/plus.gif" alt="" border="0"> &nbsp; Show Serious Adverse Events
      </a>
    </div>
      </div>

  <br>
  <br>
  <img src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20Versus%20Placebo%20or%20Leuprorelin%20Acetate%20in%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/triangle.gif" alt=""><span class="header2">&nbsp; Other Adverse Events</span>
  <a name="othr" id="othr"></a>
  <div class="header3 indent2">

      <div style="margin-top:1.0ex;">
      <a title="Show other adverse events" href="https://clinicaltrials.gov/ct2/show/results/NCT00797225?sect=X401256#othr">
        <img style="float:left" src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20Versus%20Placebo%20or%20Leuprorelin%20Acetate%20in%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/plus.gif" alt="" border="0"> &nbsp; Show Other Adverse Events
      </a>
    </div>
      </div>
</div>
  
<!-- limitations and caveats section -->
<div class="indent1">

  <br>
  <br>
  <img src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20Versus%20Placebo%20or%20Leuprorelin%20Acetate%20in%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/triangle.gif" alt=""><span class="header2">&nbsp; Limitations and Caveats</span>

  <a name="limit" id="limit"></a>
  <div class="header3 indent2">

        <div style="margin-top:1.0ex;">
      <a title="Hide Limitations and Caveats" href="https://clinicaltrials.gov/ct2/show/results/NCT00797225?sect=X0126#limit">
        <img style="float:left" src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20Versus%20Placebo%20or%20Leuprorelin%20Acetate%20in%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/minus.gif" alt="" border="0"> &nbsp; Hide Limitations and Caveats
      </a>
    </div>

    <br>
    <table class="data_table" style="margin-top:0.5ex" width="100%" cellspacing="0" cellpadding="5" border="1">
      <tbody><tr>
        <th class="header3 bold_more_info_color" style="text-align:left;">
          Limitations of the study, such as early termination leading to small numbers of participants
          analyzed and technical problems with measurement leading to unreliable or uninterpretable data
        </th>
      </tr>
      <tr>
        <td class="body3 pale_more_info_color" style="vertical-align:top;">
                      No text entered.
                  </td>
      </tr>
    </tbody></table>

    </div>
</div>
  
<!-- more results info section -->
<br>
<div class="indent1">

  <br>
  <img src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20Versus%20Placebo%20or%20Leuprorelin%20Acetate%20in%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/triangle.gif" alt=""><span class="header2">&nbsp; More Information</span>
  <a name="more" id="more"></a>
  <div class="header3 indent2">

        <div style="margin-top:1.0ex;">
      <a title="Hide more information" href="https://clinicaltrials.gov/ct2/show/results/NCT00797225?sect=X0125#more">
        <img style="float:left" src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20Versus%20Placebo%20or%20Leuprorelin%20Acetate%20in%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/minus.gif" alt="" border="0"> &nbsp; Hide More Information
      </a>
    </div>

    <br>
    <div class="body3">

          <span class="header3">Certain Agreements: &nbsp; </span>
      <table class="layout_table" style="margin-top:0.5ex; border:1px solid #ccc;" width="100%" cellspacing="0" cellpadding="5">
              <tbody><tr>
          <td class="body3 pale_more_info_color">
                          Principal Investigators are <b>NOT</b> employed by the organization sponsoring the study.
                      </td>
        </tr>
      
              <tr>
          <td class="body3 pale_more_info_color">
                          There <b>IS</b> an agreement between Principal Investigators and the Sponsor (or its agents) that restricts
              the PI's rights to discuss or publish trial results after the trial is completed.
                      </td>
        </tr>
      
              <tr>
          <td class="body3 pale_more_info_color">
          The agreement is:<br>

          <table class="layout_table" cellspacing="0" cellpadding="5" border="0">
            <tbody><tr style="vertical-align:middle;">
              <td class="header1" style="white-space:nowrap;">
                <img src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20Versus%20Placebo%20or%20Leuprorelin%20Acetate%20in%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/uncheck.gif" alt="unchecked">              </td>
              <td class="body3">
                The only disclosure restriction on the PI is that the 
sponsor can review results communications prior to public release
                and can embargo communications regarding trial results 
for a period that is <b>less than or equal to 60 days</b>.
                The sponsor cannot require changes to the communication and cannot extend the embargo.
              </td>
            </tr>
            <tr style="vertical-align:middle;">
              <td class="header1" style="white-space:nowrap;">
                <img src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20Versus%20Placebo%20or%20Leuprorelin%20Acetate%20in%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/uncheck.gif" alt="unchecked">              </td>
              <td class="body3">
                The only disclosure restriction on the PI is that the 
sponsor can review results communications prior to public release
                and can embargo communications regarding trial results 
for a period that is <b>more than 60 days but less than
                or equal to 180 days</b>. The sponsor cannot require changes to the communication and cannot extend the embargo.
              </td>
            </tr>
            <tr class="banner_color" style="vertical-align:middle;">
              <td class="header1" nowrap="nowrap">
                <img src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20Versus%20Placebo%20or%20Leuprorelin%20Acetate%20in%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/check.gif" alt="checked">              </td>
              <td class="body3">
                Other disclosure agreement that restricts the right of 
the PI to discuss or publish trial results after the trial is completed.
                                  <br>
                  <br>
                  <span class="header3">Restriction Description:</span> 
&nbsp;
                                      AbbVie requests that any 
investigator or institution that plans on presenting/publishing results 
disclosure, provide written notification of their request 60 days prior 
to their presentation/publication. AbbVie requests that no 
presentation/publication will be instituted until 12 months after a 
study is completed, or after the first presentation/publication 
whichever occurs first. A delay may be proposed of a 
presentation/publication if AbbVie needs to secure patent or proprietary
 protection.
                                                </td>
            </tr>
          </tbody></table>
          </td>
        </tr>
            </tbody></table>
    
    <br>
          <br>
            <span class="header3">Results Point of Contact: &nbsp; </span>
      <div class="indent2" style="margin-top:1ex">
        Name/Title: Global Medical Services<br>
                  Organization: AbbVie<br>
                          phone: 800-633-9110<br>
                      </div>
      <br>
    
    <br>

    
    
    
    <br>
    <table class="layout_table" cellspacing="0" cellpadding="0" border="0">
            <tbody><tr style="vertical-align:top;">
        <td nowrap="nowrap">Responsible Party:</td>
        <td style="padding-left:1em">AbbVie</td>
      </tr>
            <tr style="vertical-align:top;">
        <td nowrap="nowrap">ClinicalTrials.gov Identifier:</td>
        <td style="padding-left:1em">
          <a title="Current version of study NCT00797225 on ClinicalTrials.gov" href="https://clinicaltrials.gov/show/NCT00797225">NCT00797225</a> &nbsp; &nbsp;
          <a href="https://clinicaltrials.gov/ct2/archive/NCT00797225" title="Historical versions of study NCT00797225 on ClinicalTrials.gov Archive Site" onclick="openNewWindow('/ct2/archive/NCT00797225'); return false;">History of Changes</a>
        </td>
      </tr>
                  <tr style="vertical-align:top;">
        <td headers="colTitle" nowrap="nowrap">Other Study ID Numbers:</td>
        <td headers="colData" style="padding-left:1em">
                                    NBI-56418-0703 <br>
                                                2007-006474-28 ( EudraCT Number )<br>
                              </td>
      </tr>
      
            <tr style="vertical-align:top;">
        <td nowrap="nowrap">First Submitted:</td>
        <td style="padding-left:1em">November 21, 2008</td>
      </tr>
                  <tr style="vertical-align:top;">
        <td nowrap="nowrap">First Posted:</td>
        <td style="padding-left:1em">November 25, 2008</td>
      </tr>
                  <tr style="vertical-align:top;">
        <td nowrap="nowrap">Results First Submitted:</td>
        <td style="padding-left:1em">August 9, 2018</td>
      </tr>
                  <tr style="vertical-align:top;">
        <td nowrap="nowrap">Results First Posted:</td>
        <td style="padding-left:1em">September 10, 2018</td>
      </tr>
            <tr style="vertical-align:top;">
        <td nowrap="nowrap">Last Update Posted:</td>
        <td style="padding-left:1em">September 10, 2018
        </td>
      </tr>

    </tbody></table>

    </div>
    </div>
</div>

<br>
<br>
<br>
</div>
<div id="to-top"><a href="#wrapper">To Top</a></div>
</div>


	<div style="clear:both;"></div>
</div> 

<div>       <div id="for-footer">
        <ul class="horz-list">
            <li style="border-left:0;"><a href="https://clinicaltrials.gov/ct2/help/for-patient">For Patients and Families</a></li>
            <li><a href="https://clinicaltrials.gov/ct2/help/for-researcher">For Researchers</a></li>
            <li><a href="https://clinicaltrials.gov/ct2/help/for-manager">For Study Record Managers</a></li>
        </ul>
    </div>

</div>  
<div id="footer-menu">
    <ul class="horz-list" style="padding-bottom:1.5ex;">
		<li><a href="https://clinicaltrials.gov/ct2/home" style="white-space:nowrap">Home</a></li>
		<li><a href="https://clinicaltrials.gov/ct2/resources/rss" style="white-space:nowrap">RSS Feeds</a></li>
		<li><a href="https://clinicaltrials.gov/ct2/sitemap" style="white-space:nowrap">Site Map</a></li>
		<li><a href="https://clinicaltrials.gov/ct2/about-site/terms-conditions" style="white-space:nowrap">Terms and Conditions</a></li>
		<li><a href="https://clinicaltrials.gov/ct2/about-site/disclaimer" style="white-space:nowrap">Disclaimer</a></li>
		<li><a href="https://support.nlm.nih.gov/knowledgebase/category/?id=CAT-01242&amp;category=clinicaltrials.gov&amp;hd_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2Fresults%2FNCT00797225%3Fsect%3DX01256" style="white-space:nowrap" onclick="openNewWindow('https://support.nlm.nih.gov/knowledgebase/category/?id=CAT-01242&amp;category=clinicaltrials.gov&amp;hd_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2Fresults%2FNCT00797225%3Fsect%3DX01256'); return false">Customer Support</a></li>
	</ul>
</div>

</div>  
<div id="fine-print">
	<ul class="horz-list">
		<li><a title="NLM copyright information - opens new window" href="https://www.nlm.nih.gov/copyright.html" onclick="openNewWindow('https://www.nlm.nih.gov/copyright.html'); return false">Copyright</a></li>
		<li><a title="NLM privacy policy - opens new window" href="https://www.nlm.nih.gov/privacy.html" onclick="openNewWindow('https://www.nlm.nih.gov/privacy.html'); return false">Privacy</a></li>
		<li><a href="https://clinicaltrials.gov/ct2/accessibility" title="NLM Accessibility">Accessibility</a></li>
		<li><a title="NLM viewers and players - opens new window" href="https://www.nlm.nih.gov/plugins.html" onclick="openNewWindow('https://www.nlm.nih.gov/plugins.html'); return false">Viewers and Players</a></li>
		<li><a title="NIH Freedom of Information Act office - opens new window" href="https://www.nih.gov/icd/od/foia/index.htm" onclick="openNewWindow('https://www.nih.gov/icd/od/foia/index.htm'); return false">Freedom of Information Act</a></li>
		<li class="last-item"><a title="USA.gov - opens new window" href="https://www.usa.gov/" onclick="openNewWindow('https://www.usa.gov/'); return false">USA.gov</a></li>
	</ul>
    <ul class="horz-list">
       <li><a title="U.S. National Library of Medicine - opens new window" href="https://www.nlm.nih.gov/" onclick="openNewWindow('https://www.nlm.nih.gov/'); return false">U.S. National Library of Medicine</a></li>
       <li><a title="U.S. National Institutes of Health - opens new window" href="https://www.nih.gov/" onclick="openNewWindow('https://www.nih.gov/'); return false">U.S. National Institutes of Health</a></li>
       <li class="last-item"><a title="U.S. Department of Health and Human Services - opens new window" href="https://www.hhs.gov/" onclick="openNewWindow('https://www.hhs.gov/'); return false">
            U.S. Department of Health and Human Services</a></li>
    </ul>
</div>

<script type="text/javascript">__ncbi_sg_gaMode="clinicaltrials"</script>
<script type="text/javascript" src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20Versus%20Placebo%20or%20Leuprorelin%20Acetate%20in%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/instrumentNCBIBaseJS.js"></script><script async="1" src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20Versus%20Placebo%20or%20Leuprorelin%20Acetate%20in%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/analytics.js"></script><noscript></noscript>
<script type="text/javascript" src="Efficacy%20and%20Safety%20Study%20of%20Elagolix%20Versus%20Placebo%20or%20Leuprorelin%20Acetate%20in%20Endometriosis%20-%20Study%20Results%20-%20ClinicalTrials.gov_files/main-glossary.js"></script><noscript></noscript>



<ul class="print-log"><li></li></ul></body></html>